

**JOINT**

**APPLICATION  
FOR  
UNITED STATES LETTERS PATENT**

TO THE COMMISSIONER FOR PATENTS:

BE IT KNOWN, that I/we,

**Jane Daun**, Newton, MA, USA  
**Heather A. Davis**, Haverhill, MA, USA  
**Bruce DeCosta**, Salem, NH, USA  
**Scott Field**, Towaco, NJ, USA  
**Fabian Gusovsky**, Andover, MA USA  
**Ieharu Hishinuma**, Ibaraki, JAPAN  
**Yimin Jiang**, Londonderry, NH USA  
**Toshihiko Kaneko**, Ibaraki, JAPAN  
**Kouichi Kikuchi**, Ibaraki, JAPAN  
**Seiichi Kobayashi**, Belmont, MA USA  
**André Lescarbeau**, Somerville, MA USA  
**Xiang-Yi Li**, Andover, MA USA  
**Kenzo Muramoto**, Ibaraki, JAPAN  
**Norihito Ohi**, Ibaraki, JAPAN  
**Marc Pesant**, Andover, MA USA  
**Boris M. Seletsky**, Andover, MA USA  
**Motohiro Soejima**, Ibaraki, JAPAN  
**Lynda Tremblay**, Tewksbury, MA USA  
**Ye Yao**, North Andover, MA USA  
**Hiromitsu Yokohama**, Ibaraki, JAPAN  
**Yan Zhao**, North Andover, MA USA  
**Wanjun Zheng**, Londonderry, NH USA

have invented certain new and useful improvements in **NOVEL DEAZAPURINES AND USES THEREOF** of which the following is a specification:

## ***NOVEL DEAZAPURINES AND USES THEREOF***

### **PRIORITY CLAIM**

**[0001]** The present Application is a Continuation-In-Part and claims the benefit under 35 U.S.C. § 120 of co-pending International Application No.: PCT/US03/00366, filed January 7, 2003 and published in English under PCT Article 21(2), which claims priority to U.S. Provisional Patent Application Number 60/346,598, filed January 7, 2002; the entire contents of each of these applications are incorporated herein by reference.

### **BACKGROUND OF THE INVENTION**

**[0002]** Inflammation is a process resulting from the dilation and increased permeability of blood vessels at site of injury or infection. Chemokines and cytokines released at the site increase the expression of cell surface proteins on endothelial cells, allowing circulating leukocytes to stick to the vessel wall and migrate to the site of injury/infection within the tissue. These cell surface proteins, termed "cell adhesion molecules" allow the interaction between the leukocytes and the endothelial cells, and mediate the migration of leukocytes into the tissue. Additionally, cell adhesion molecules are required for many of the cell-to-cell interactions in the inflammatory and immune responses. There are three classes of adhesion molecules: selectins, integrins and immunoglobulin-related proteins which can be expressed on leukocytes and endothelial cells. Several of the adhesion molecules, including E-selectin and ICAM, are induced by cytokines such as IL-1 and TNF, and their expression is mediated by the transcriptional factor, NF- $\kappa$ B.

**[0003]** Sustained or inappropriate expression of adhesion molecules can lead to inflammatory or autoimmune disorders. Exaggerated expression of E-selectin and/or ICAM can result in chronic inflammation and has been associated with several inflammatory or autoimmune disorders. Therefore, inhibitors of cell adhesion molecules may be useful for the treatment of these diseases.


**[0004]** Inflammatory and autoimmune diseases are not well managed by current therapy and developments of better drugs are widely pursued. For example, rheumatoid arthritis is a state of chronic inflammation within the joint characterized by cartilage and bone destruction. Traditional therapies for inflammatory or autoimmune disease, such as rheumatoid arthritis,

include nonsteroidal anti-inflammatory drugs and salicylates, gold compounds, hydroxychloroquine, sulfasalazine, corticosteroids, oral penicillamines, and cytotoxic or immunosuppressive drugs. However, many of these therapies are not always sufficiently effective and have resulted in serious side effects. More recently, injectable forms of TNF $\alpha$  neutralizing proteins have been successfully marketed for the treatment of rheumatoid arthritis and Crohn's Disease; however, an orally available inhibitor has not been developed for these inflammatory or autoimmune diseases.

[0005] Clearly, there remains a need to identify new classes of therapeutic agents for the treatment of inflammatory or autoimmune and proliferative diseases, preferably that are orally available, and are free of serious side effects. It would also be desirable to define new classes of therapeutic agents for the treatment of inflammatory or autoimmune and proliferative disorders in general.

#### SUMMARY OF THE INVENTION

[0006] As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides methods of using novel compounds of general formula (I),



(I)

and/or pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, in the treatment of reperfusion injuries, osteoporosis and/or bone metastasis.


#### DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS OF THE INVENTION

[0007] In recognition of the need to investigate and define new classes of therapeutic agents for the treatment of rheumatoid arthritis and other disorders (in certain embodiments, inflammatory or autoimmune and proliferative disorders), the present invention provides novel deazapurines and analogues thereof, as described in more detail herein, which are useful

generally in the treatment of inflammatory or autoimmune and proliferative disorders. In certain embodiments, the compounds of the present invention can be used for the treatment of diseases and disorders including, but not limited to, rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, urticaria, allergic rhinitis, myasthenia gravis, diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, reperfusion injury, bone metastasis, bone resorption disorders, such as osteoporosis, and cancer.

**[0008]**     1) *General Description of Compounds of the Invention*

**[0009]**     The compounds of the invention include compounds of the general formula **(I)** (and tautomers thereof) as further defined below:



**(I)**

and pharmaceutically acceptable derivatives thereof;

wherein n is an integer from 0-4;

R<sub>1</sub> is hydrogen, -NH<sub>2</sub>, -NHMe, -NHAc, -OH, F, -OMe, -CN, or -NH(C=O)OEt;

R<sub>2</sub> is hydrogen, -NR<sub>A</sub>R<sub>B</sub>, -OR<sub>A</sub>, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R<sub>A</sub> and R<sub>B</sub> are each independently hydrogen or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;


each occurrence of R<sub>3</sub> is independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group -G-R<sub>C</sub>, wherein G is absent or is -CH<sub>2</sub>-, -NR<sub>D</sub>-, -O-, or (C=O), and wherein R<sub>C</sub> is hydrogen, -NR<sub>F</sub>R<sub>G</sub>, -OR<sub>F</sub>, -SR<sub>F</sub>, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R<sub>D</sub>, R<sub>F</sub> and R<sub>G</sub> are each independently hydrogen, -NR<sub>x</sub>R<sub>y</sub>, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R<sub>D</sub> and R<sub>C</sub> or R<sub>F</sub> and R<sub>G</sub> taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered



substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of  $R_x$  and  $R_y$  is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein  $R_x$  and  $R_y$  taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

**[0010]** In certain embodiments, the present invention defines certain classes of compounds which are of special interest. For example, one class of compounds of special interest includes those compounds substituted with two occurrences of  $R_3$  in which the compound has the structure:




wherein  $R_{3a}$  and  $R_{3b}$  are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group  $-G-R_C$ , wherein  $G$  is absent,  $-CH_2-$ ,  $-NR_D-$ ,  $-O-$ , or  $(C=O)$ , and wherein  $R_C$  is hydrogen,  $-NR_F R_G$ ,  $-OR_F$ ,  $-SR_F$ , or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein  $R_D$ ,  $R_F$  and  $R_G$  are each independently hydrogen,  $-NR_x R_y$ , an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein  $R_D$  and  $R_C$  or  $R_F$  and  $R_G$  taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of  $R_x$  and  $R_y$  is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein  $R_x$  and  $R_y$  taken together are a 4-, 5- or 6-

membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.


[0011] Another class of compounds of special interest comprises compounds having the structure:



wherein R<sub>3a</sub> and R<sub>3b</sub> are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group -G-R<sub>C</sub>, wherein G is absent, -CH<sub>2</sub>-, -NR<sub>D</sub>-, -O-, or (C=O), and wherein R<sub>C</sub> is hydrogen, -NR<sub>F</sub>R<sub>G</sub>, -OR<sub>F</sub>, -SR<sub>F</sub>, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R<sub>D</sub>, R<sub>F</sub> and R<sub>G</sub> are each independently hydrogen, -NR<sub>x</sub>R<sub>y</sub>, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R<sub>D</sub> and R<sub>C</sub> or R<sub>F</sub> and R<sub>G</sub> taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R<sub>x</sub> and R<sub>y</sub> is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R<sub>x</sub> and R<sub>y</sub> taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;


whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

[0012] Another class of compounds of special interest comprises compounds having the structure of formula (I) in which  $R_{3a}$  is  $-\text{CH}_2\text{NR}_F\text{R}_G$  and  $R_{3b}$  is hydrogen and the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined generally above and in classes and subclasses herein.

[0013] Another class of compounds of special interest comprises compounds having the structure of formula (I) in which  $R_{3b}$  is  $-\text{CH}_2\text{NR}_F\text{R}_G$  and  $R_{3a}$  is hydrogen and the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined generally above and in classes and subclasses herein.

[0014] Another class of compounds of special interest comprises compounds having the structure of formula (I) in which  $R_{3c}$  is  $-\text{CH}_2\text{NR}_F\text{R}_G$  and  $R_{3d}$  is hydrogen and the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined generally above and in classes and subclasses herein.

**[0015]** Another class of compounds of special interest comprises compounds having the structure of formula (I) in which  $R_{3a}$  is  $-(CH=CH)_qCH_2(CH_2)_rNR_F R_G$  and  $R_{3b}$  is hydrogen and the compound has the structure:




wherein  $q$  and  $r$  are each independently 0 or 1; and  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined generally above and in classes and subclasses herein.

**[0016]** Another class of compounds of special interest comprises compounds having the structure of formula (I) in which  $R_{3a}$  is hydrogen and  $R_{3b}$  is  $-(CH=CH)_qCH_2(CH_2)_rNR_F R_G$  and the compound has the structure:




wherein  $q$  and  $r$  are each independently 0 or 1; and  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined generally above and in classes and subclasses herein.

**[0017]** Another class of compounds of special interest includes compounds having the structure of formula (I) in which  $R_{3a}$  is  $-(C=O)NR_F R_G$  and  $R_{3b}$  is hydrogen and the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined generally above and in classes and subclasses herein.

[0018] Another class of compounds of special interest includes compounds having the structure of formula (I) in which  $R_{3b}$  is  $-(C=O)NR_F R_G$  and  $R_{3a}$  is hydrogen and the compound has the structure:



wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined generally above and in classes and subclasses herein.

[0019] Another class of compounds of special interest comprises compounds having the structure of formula (I) in which  $R_{3a}$  is  $-CH_2S(=O)_mNR_F R_G$  and  $R_{3b}$  is hydrogen and the compound has the structure:




wherein  $R_1$  and  $R_2$  are as defined generally above and in classes and subclasses herein;  
 $m$  is 0, 1 or 2; and

$R_F$  is an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

[0020] Another class of compounds of special interest comprises compounds having the structure of formula (I) in which  $R_{3a}$  is  $-\text{CH}_2\text{OR}_F$  and  $R_{3b}$  is hydrogen and the compound has the structure:



wherein  $R_1$  and  $R_2$  are as defined generally above and in classes and subclasses herein;  
and

$R_F$  is hydrogen, a protective group or an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

[0021] A number of important subclasses of each of the foregoing classes deserve separate mention; these subclasses include subclasses of the foregoing classes in which:

[0022] i)  $R_1$  is  $\text{NH}_2$ ;

[0023] ii)  $R_1$  is hydrogen;

[0024] iii)  $R_1$  is  $\text{NHMe}$ ;

[0025] iv)  $R_1$  is  $\text{NHAc}$ ;

[0026] v)  $R_2$  is  $\text{NH}_2$ ,  $\text{OH}$ ,  $\text{C}_1\text{-C}_6$  alkyl or  $\text{C}_1\text{-C}_6$  alkenyl, said alkyl and alkenyl groups optionally substituted with halogen or hydroxyl;

[0027] vi)  $R_2$  is  $\text{C}_1\text{-C}_2$  alkyl;

[0028] vii) R<sub>2</sub> is methyl;

[0029] viii) R<sub>2</sub> is hydrogen;

[0030] ix) one of R<sub>F</sub> or R<sub>G</sub> is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R<sub>F</sub> and R<sub>G</sub> taken together are a 6-membered substituted or unsubstituted heterocyclic moiety;

[0031] x) one of R<sub>F</sub> or R<sub>G</sub> is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R<sub>F</sub> and R<sub>G</sub> taken together are a 6-membered substituted or unsubstituted cyclic or heterocyclic moiety;

[0032] xi) one of R<sub>F</sub> or R<sub>G</sub> is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluoromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl; and


[0033] xii) one of R<sub>F</sub> or R<sub>G</sub> is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino;

[0034] xiii) R<sub>F</sub> is an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl; and/or

[0035] xiv) R<sub>F</sub> is hydrogen, a protecting group, or an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

[0036] As the reader will appreciate, compounds of particular interest include, among others, those which share the attributes of one or more of the foregoing subclasses. Some of those subclasses are illustrated by the following sorts of compounds:

[0037] *I) Compounds of the formula (and pharmaceutically acceptable derivatives thereof):*



wherein  $R_1$  and  $R_2$  are as defined generically and in classes and subclasses herein;  $G$  is  $CH_2$  or  $-(C=O)-$  and one of  $R_G$  or  $R_F$  is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein  $R_F$  and  $R_G$  taken together are a 3 to 8-membered substituted or unsubstituted cyclic or heterocyclic moiety.


[0038] In certain embodiments, one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein  $R_F$  and  $R_G$  taken together are a 3 to 8-membered substituted or unsubstituted cyclic or heterocyclic moiety.

[0039] In certain other embodiments, one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluoromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.

[0040] In still other embodiments, one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.

[0041] *II) Compounds of the formula (and pharmaceutically acceptable derivatives thereof):*






wherein  $R_1$  and  $R_2$  are as defined generically and in classes and subclasses herein; G is  $\text{CH}_2$  or  $-(\text{C}=\text{O})$  and X is O, S,  $\text{C}=\text{O}$ ,  $\text{S}=\text{O}$ ,  $\text{C}=\text{CR}_4\text{R}_5$ ,  $\text{NR}_4$ , or  $\text{CR}_4\text{R}_5$ ; wherein each occurrence of  $R_4$  and  $R_5$  is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

**[0042] III) Compounds of the formula (and pharmaceutically acceptable derivatives thereof):**



wherein  $R_1$  and  $R_2$  are as defined generically and in classes and subclasses herein; G is  $\text{CH}_2$  or  $-(\text{C}=\text{O})$  and one of  $R_G$  or  $R_F$  is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein  $R_F$  and  $R_G$  taken together are a 3 to 8-membered substituted or unsubstituted cyclic or heterocyclic moiety.


**[0043]** In certain embodiments, one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for

each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R<sub>F</sub> and R<sub>G</sub> taken together are a 3 to 8-membered substituted or unsubstituted cyclic or heterocyclic moiety.

[0044] In certain other embodiments, one of R<sub>F</sub> or R<sub>G</sub> is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluoromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.

[0045] In still other embodiments, one of R<sub>F</sub> or R<sub>G</sub> is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.


[0046] *IV) Compounds of the formula (and pharmaceutically acceptable derivatives thereof):*



wherein R<sub>1</sub> and R<sub>2</sub> are as defined generically and in classes and subclasses herein; G is CH<sub>2</sub> or -(C=O) and X is O, S, C=O, S=O, C=CR<sub>4</sub>R<sub>5</sub>, NR<sub>4</sub>, or CR<sub>4</sub>R<sub>5</sub>; wherein each occurrence of R<sub>4</sub> and R<sub>5</sub> is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

[0047] *V) Compounds of the formula (and pharmaceutically acceptable derivatives thereof):*




wherein  $R_1$  and  $R_2$  are as defined generically and in classes and subclasses herein;  $G$  is  $CH_2$  or  $-(C=O)$  and one of  $R_G$  or  $R_F$  is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein  $R_F$  and  $R_G$  taken together are a 3 to 8-membered substituted or unsubstituted cyclic or heterocyclic moiety.

[0048] In certain embodiments, one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein  $R_F$  and  $R_G$  taken together are a 3 to 8-membered substituted or unsubstituted cyclic or heterocyclic moiety.

[0049] In certain other embodiments, one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluoromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.

[0050] In still other embodiments, one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.


[0051] **VI) Compounds of the formula (and pharmaceutically acceptable derivatives thereof):**



wherein  $R_1$  and  $R_2$  are as defined generically and in classes and subclasses herein; G is  $\text{CH}_2$  or  $-(\text{C}=\text{O})$  and X is O, S,  $\text{C}=\text{O}$ ,  $\text{S}=\text{O}$ ,  $\text{C}=\text{CR}_4\text{R}_5$ ,  $\text{NR}_4$ , or  $\text{CR}_4\text{R}_5$ ; wherein each occurrence of  $R_4$  and  $R_5$  is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.


[0052] **VII) Compounds of the formula (and pharmaceutically acceptable derivatives thereof):**




wherein  $R_F$ ,  $R_1$  and  $R_2$  are as defined generically and in classes and subclasses herein; p is an integer from 0-3; s is an integer from 0-4; A, B, D, E and each occurrence of K are independently absent, O, S,  $\text{C}=\text{O}$ ,  $\text{S}=\text{O}$ ,  $\text{C}=\text{CR}_4\text{R}_5$ ,  $\text{NR}_4$ , or  $\text{CR}_4\text{R}_5$ , wherein each occurrence of  $R_4$  and  $R_5$  is independently hydrogen, hydroxyl, halogen, cyano,  $-\text{OR}_x$ ,  $-\text{SR}_x$ ,  $-\text{NR}_x\text{R}_y$ , an

aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and wherein A and B, B and D, D and E, E and K and any two adjacent K groups may be linked by a single or double bond as valency permits; wherein each occurrence of  $R_x$  and  $R_y$  is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moiety,


whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl, heteroaryl aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moieties may be independently substituted or unsubstituted.




[0053] In certain exemplary embodiments, represents a substituted or unsubstituted



phenyl, pyridyl or furanyl moiety. In certain other embodiments, represents a substituted or unsubstituted, saturated or unsaturated 3-, 4-, 5-, 6-, 7-, or 8-membered cycloalkyl



or cycloheteroalkyl moiety. In certain exemplary embodiments, represents substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. In



certain exemplary embodiments, represents a substituted or unsubstituted bicyclic aliphatic moiety.


[0054] In certain exemplary embodiments,  $R_F$  is hydrogen or lower alkyl. In certain embodiments,  $R_F$  is hydrogen or methyl.

[0055] It will also be appreciated that for each of the subgroups I-VII described above, a variety of other subclasses are of special interest, including, but not limited to those classes


described above i)-xiv) and classes, subclasses and species of compounds described above and in the examples herein.

[0056] Some of the foregoing compounds can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, *e.g.*, stereoisomers and/or diastereomers. Thus, inventive compounds and pharmaceutical compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers. In certain embodiments, the compounds of the invention are enantiopure compounds. In certain other embodiments, a mixture of stereoisomers or diastereomers are provided.

[0057] Additionally, any and all tautomers of the foregoing compounds are encompassed by the invention. The invention is not limited to the tautomeric structures depicted herein. As but one example, compounds described and depicted generally as:



may also be described and depicted as:



[0058] Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated. The invention additionally encompasses the compounds as individual isomers substantially free of other isomers and alternatively, as mixtures of various isomers, *e.g.*, racemic mixtures of stereoisomers. In addition to the above-mentioned compounds *per se*, this invention also encompasses pharmaceutically acceptable derivatives of these compounds and compositions

comprising one or more compounds of the invention and one or more pharmaceutically acceptable excipients or additives.

[0059] Compounds of the invention may be prepared by crystallization of compound of formula (I) under different conditions and may exist as one or a combination of polymorphs of compound of general formula (I) forming part of this invention. For example, different polymorphs may be identified and/or prepared by using different solvents, or different mixtures of solvents for recrystallization; by performing crystallizations at different temperatures; or by using various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffractogram and/or other techniques. Thus, the present invention encompasses inventive compounds, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

[0060] *2) Compounds and Definitions*

[0061] As discussed above, this invention provides novel compounds with a range of biological properties. Compounds of this invention have biological activities relevant for the treatment of inflammatory or autoimmune disorders and/or proliferative disorders. In certain embodiments, the compounds of the invention are useful for the treatment of rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, urticaria, allergic rhinitis, myasthenia gravis, diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, reperfusion injury, bone metastasis, bone resorption disorders, such as osteoporosis, and cancer.

[0062] Compounds of this invention include those specifically set forth above and described herein, and are illustrated in part by the various classes, subgenera and species disclosed elsewhere herein.

[0063] Additionally, the present invention provides pharmaceutically acceptable derivatives of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents. The phrase, “pharmaceutically acceptable derivative”, as used herein, denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of such compound, or any other adduct or derivative which, upon administration to a patient, is capable of providing (directly or indirectly) a compound as otherwise described herein, or a metabolite or residue thereof. Pharmaceutically acceptable derivatives thus include among others pro-drugs. A pro-drug is a derivative of a compound, usually with significantly reduced pharmacological activity, which contains an additional moiety which is susceptible to removal *in vivo* yielding the parent molecule as the pharmacologically active species. An example of a pro-drug is an ester which is cleaved *in vivo* to yield a compound of interest. Pro-drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs, are known and may be adapted to the present invention. Certain exemplary pharmaceutical compositions and pharmaceutically acceptable derivatives will be discussed in more detail herein below.

[0064] Certain compounds of the present invention, and definitions of specific functional groups are also described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75<sup>th</sup> Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, the entire contents of which are incorporated herein by reference. Furthermore, it will be appreciated by one of ordinary skill in the art that the synthetic methods, as described herein, utilize a variety of protecting groups. By the term “protecting group”, as used herein, it is meant that a particular functional moiety, *e.g.*, O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound. In preferred embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group must be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the other functional groups; the protecting group forms an



easily separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction. As detailed herein, oxygen, sulfur, nitrogen and carbon protecting groups may be utilized. For example, in certain embodiments, as detailed herein, certain exemplary oxygen protecting groups are utilized. These oxygen protecting groups include, but are not limited to methyl ethers, substituted methyl ethers (*e.g.*, MOM (methoxymethyl ether), MTM (methylthiomethyl ether), BOM (benzyloxymethyl ether), PMBM (p-methoxybenzyloxymethyl ether), to name a few), substituted ethyl ethers, substituted benzyl ethers, silyl ethers (*e.g.*, TMS (trimethylsilyl ether), TES (triethylsilyl ether), TIPS (triisopropylsilyl ether), TBDMS (t-butyltrimethylsilyl ether), tribenzyl silyl ether, TBDPS (t-butyl-diphenyl silyl ether), to name a few), esters (*e.g.*, formate, acetate, benzoate (Bz), trifluoroacetate, dichloroacetate, to name a few), carbonates, cyclic acetals and ketals. In certain other exemplary embodiments, nitrogen protecting groups are utilized. These nitrogen protecting groups include, but are not limited to, carbamates (including methyl, ethyl and substituted ethyl carbamates (*e.g.*, Troc), to name a few) amides, cyclic imide derivatives, N-Alkyl and N-Aryl amines, imine derivatives, and enamine derivatives, to name a few. Certain other exemplary protecting groups are detailed herein, however, it will be appreciated that the present invention is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the present invention. Additionally, a variety of protecting groups are described in "Protective Groups in Organic Synthesis" Third Ed. Greene, T.W. and Wuts, P.G., Eds., John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.

**[0065]** It will be appreciated that the compounds, as described herein, may be substituted with any number of substituents or functional moieties. In general, the term "substituted" whether preceded by the term "optionally" or not, and substituents contained in formulas of this invention, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic,

aromatic and nonaromatic substituents of organic compounds. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. Furthermore, this invention is not intended to be limited in any manner by the permissible substituents of organic compounds. Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful in the treatment, for example of inflammatory or autoimmune and proliferative disorders, including, but not limited to rheumatoid arthritis, psoriasis, asthma and cancer. The term "stable", as used herein, preferably refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.

**[0066]** The term "aliphatic", as used herein, includes both saturated and unsaturated, straight chain (*i.e.*, unbranched), branched, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups. As will be appreciated by one of ordinary skill in the art, "aliphatic" is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties. Thus, as used herein, the term "alkyl" includes straight, branched and cyclic alkyl groups. An analogous convention applies to other generic terms such as "alkenyl", "alkynyl" and the like. Furthermore, as used herein, the terms "alkyl", "alkenyl", "alkynyl" and the like encompass both substituted and unsubstituted groups. In certain embodiments, as used herein, "lower alkyl" is used to indicate those alkyl groups (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-6 carbon atoms.

**[0067]** In certain embodiments, the alkyl, alkenyl and alkynyl groups employed in the invention contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-4 carbon atoms. Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-

propyl, isopropyl, cyclopropyl, -CH<sub>2</sub>-cyclopropyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclobutyl, -CH<sub>2</sub>-cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, cyclopentyl, -CH<sub>2</sub>-cyclopentyl-n, hexyl, sec-hexyl, cyclohexyl, -CH<sub>2</sub>-cyclohexyl moieties and the like, which again, may bear one or more substituents. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like.

**[0068]** The term “alkoxy” (or “alkyloxy”), or “thioalkyl” as used herein refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom or through a sulfur atom. In certain embodiments, the alkyl group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms. Examples of alkoxy, include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy and n-hexoxy. Examples of thioalkyl include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, n-butylthio, and the like.

**[0069]** The term “alkylamino” refers to a group having the structure -NHR' wherein R' is alkyl, as defined herein. The term “aminoalkyl” refers to a group having the structure NH<sub>2</sub>R'-, wherein R' is alkyl, as defined herein. In certain embodiments, the alkyl group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms. Examples of alkylamino include, but are not limited to, methylamino, ethylamino, iso-propylamino and the like.

**[0070]** Some examples of substituents of the above-described aliphatic (and other) moieties of compounds of the invention include, but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -OH; -NO<sub>2</sub>; -CN; -CF<sub>3</sub>; -CH<sub>2</sub>CF<sub>3</sub>; -CHCl<sub>2</sub>; -CH<sub>2</sub>OH; -CH<sub>2</sub>CH<sub>2</sub>OH; -CH<sub>2</sub>NH<sub>2</sub>; -CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>; -C(O)R<sub>x</sub>; -CO<sub>2</sub>(R<sub>x</sub>); -CON(R<sub>x</sub>)<sub>2</sub>; -OC(O)R<sub>x</sub>; -OCO<sub>2</sub>R<sub>x</sub>; -OCON(R<sub>x</sub>)<sub>2</sub>; -N(R<sub>x</sub>)<sub>2</sub>; -S(O)<sub>2</sub>R<sub>x</sub>; -NR<sub>x</sub>(CO)R<sub>x</sub> wherein each occurrence of R<sub>x</sub>

independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.

[0071] In general, the terms “aryl” and “heteroaryl”, as used herein, refer to stable mono- or polycyclic, heterocyclic, polycyclic, and polyheterocyclic unsaturated moieties having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted. It will also be appreciated that aryl and heteroaryl moieties, as defined herein may be attached via an aliphatic, heteroaliphatic, alkyl or heteroalkyl moiety and thus also include -(aliphatic)aryl, -(heteroaliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)heteroaryl, -(alkyl)aryl, -(heteroalkyl)aryl, -(heteroalkyl)aryl, and -(heteroalkyl)heteroaryl moieties. Thus, as used herein, the phrases “aryl or heteroaryl” and “aryl, heteroaryl, -(aliphatic)aryl, -(heteroaliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)heteroaryl, -(alkyl)aryl, -(heteroalkyl)aryl, -(heteroalkyl)aryl, and -(heteroalkyl)heteroaryl” are interchangeable. Substituents include, but are not limited to, any of the previously mentioned substituents, *i.e.*, the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound. In certain embodiments of the present invention, “aryl” refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like. In certain embodiments of the present invention, the term “heteroaryl”, as used herein, refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.

[0072] It will be appreciated that aryl and heteroaryl groups (including bicyclic aryl groups) can be unsubstituted or substituted, wherein substitution includes replacement of one, two or

three of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -OH; -NO<sub>2</sub>; -CN; -CF<sub>3</sub>; -CH<sub>2</sub>CF<sub>3</sub>; -CHCl<sub>2</sub>; -CH<sub>2</sub>OH; -CH<sub>2</sub>CH<sub>2</sub>OH; -CH<sub>2</sub>NH<sub>2</sub>; -CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>; -C(O)R<sub>x</sub>; -CO<sub>2</sub>(R<sub>x</sub>); -CON(R<sub>x</sub>)<sub>2</sub>; -OC(O)R<sub>x</sub>; -OCO<sub>2</sub>R<sub>x</sub>; -OCON(R<sub>x</sub>)<sub>2</sub>; -N(R<sub>x</sub>)<sub>2</sub>; -S(O)<sub>2</sub>R<sub>x</sub>; -NR<sub>x</sub>(CO)R<sub>x</sub> wherein each occurrence of R<sub>x</sub> independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.

**[0073]** The term “cycloalkyl”, as used herein, refers specifically to groups having three to seven, preferably three to ten carbon atoms. Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, which, as in the case of other aliphatic, heteroaliphatic or heterocyclic moieties, may optionally be substituted with substituents including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -OH; -NO<sub>2</sub>; -CN; -CF<sub>3</sub>; -CH<sub>2</sub>CF<sub>3</sub>; -CHCl<sub>2</sub>; -CH<sub>2</sub>OH; -CH<sub>2</sub>CH<sub>2</sub>OH; -CH<sub>2</sub>NH<sub>2</sub>; -CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>; -C(O)R<sub>x</sub>; -CO<sub>2</sub>(R<sub>x</sub>); -CON(R<sub>x</sub>)<sub>2</sub>; -OC(O)R<sub>x</sub>; -OCO<sub>2</sub>R<sub>x</sub>; -OCON(R<sub>x</sub>)<sub>2</sub>; -N(R<sub>x</sub>)<sub>2</sub>; -S(O)<sub>2</sub>R<sub>x</sub>; -NR<sub>x</sub>(CO)R<sub>x</sub> wherein each occurrence of R<sub>x</sub> independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.

**[0074]** The term “heteroaliphatic”, as used herein, refers to aliphatic moieties which contain one or more oxygen sulfur, nitrogen, phosphorus or silicon atoms, *e.g.*, in place of carbon atoms.

Heteroaliphatic moieties may be branched, unbranched, cyclic or acyclic and include saturated and unsaturated heterocycles such as morpholino, pyrrolidinyl, etc. In certain embodiments, heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -OH; -NO<sub>2</sub>; -CN; -CF<sub>3</sub>; -CH<sub>2</sub>CF<sub>3</sub>; -CHCl<sub>2</sub>; -CH<sub>2</sub>OH; -CH<sub>2</sub>CH<sub>2</sub>OH; -CH<sub>2</sub>NH<sub>2</sub>; -CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>; -C(O)R<sub>x</sub>; -CO<sub>2</sub>(R<sub>x</sub>); -CON(R<sub>x</sub>)<sub>2</sub>; -OC(O)R<sub>x</sub>; -OCO<sub>2</sub>R<sub>x</sub>; -OCON(R<sub>x</sub>)<sub>2</sub>; -N(R<sub>x</sub>)<sub>2</sub>; -S(O)<sub>2</sub>R<sub>x</sub>; -NR<sub>x</sub>(CO)R<sub>x</sub> wherein each occurrence of R<sub>x</sub> independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.

[0075] The terms “halo” and “halogen” as used herein refer to an atom selected from fluorine, chlorine, bromine and iodine.

[0076] The term “haloalkyl” denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.

[0077] The term “heterocycloalkyl” or “heterocycle”, as used herein, refers to a non-aromatic 5-, 6- or 7- membered ring or a polycyclic group, including, but not limited to a bi- or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to a benzene ring. Representative heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl. In certain embodiments, a “substituted heterocycloalkyl or heterocycle” group is utilized and as used

herein, refers to a heterocycloalkyl or heterocycle group, as defined above, substituted by the independent replacement of one, two or three of the hydrogen atoms thereon with but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; I; -OH; -NO<sub>2</sub>; -CN; -CF<sub>3</sub>; -CH<sub>2</sub>CF<sub>3</sub>; -CHCl<sub>2</sub>; -CH<sub>2</sub>OH; -CH<sub>2</sub>CH<sub>2</sub>OH; -CH<sub>2</sub>NH<sub>2</sub>; -CH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>; -C(O)R<sub>x</sub>; -CO<sub>2</sub>(R<sub>x</sub>); -CON(R<sub>x</sub>)<sub>2</sub>; -OC(O)R<sub>x</sub>; -OCO<sub>2</sub>R<sub>x</sub>; -OCON(R<sub>x</sub>)<sub>2</sub>; -N(R<sub>x</sub>)<sub>2</sub>; -S(O)<sub>2</sub>R<sub>x</sub>; -NR<sub>x</sub>(CO)R<sub>x</sub> wherein each occurrence of R<sub>x</sub> independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, wherein any of the aliphatic, heteroaliphatic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.

**[0078]**     3) *Research Uses, Formulation and Administration*

**[0079]**     According to the present invention, the inventive compounds may be assayed in any of the available assays known in the art for identifying compounds having a pre-determined biological activity. For example, the assay may be cellular or non-cellular, *in vivo* or *in vitro*, high- or low-throughput format, etc. In certain exemplary embodiments, the inventive compounds are tested in assays to identify those compounds having antiproliferative/anticancer activity, inflammatory cytokine signaling pathway inhibitory activity, adhesion molecule expression inhibitory activity and/or anti-inflammatory effect.

**[0080]**     Thus, in one aspect, compounds of this invention which are of particular interest include those which:

- exhibit activity generally as inhibitors of adhesion molecule expression on the endothelial cell surface upon stimulation with inflammatory cytokines;
- exhibit activity as inhibitors of inflammatory cytokine signaling pathway;
- exhibit an anti-inflammatory effect on suitable cell lines maintained *in vitro*, or in animal studies using a scientifically acceptable model;

- exhibit an antiproliferative and/or anticancer effect on suitable cell lines maintained *in vitro*, or in animal studies using a scientifically acceptable model; and
- exhibit a favorable therapeutic profile (*e.g.*, safety, efficacy, and stability).

[0081] As discussed herein, compounds of the invention have been shown to reduce activation of the transcriptional factor NF- $\kappa$ B and inhibit the transcriptional activation in inflammatory cytokine signaling pathways, which regulates many genes such as IL-1 $\alpha$  and TNF  $\alpha$  involved in the pathology of several inflammatory diseases. For example, elevated levels of TNF  $\alpha$  and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; Pagets disease; osteoporosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; pancreatic B cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF  $\alpha$ .

[0082] Certain compounds as described herein exhibit activity generally as inhibitors of cell adhesion molecules on endothelial cells (E-selectin and ICAM) and transcriptional activation induced by inflammatory cytokine signaling. More specifically, compounds of the invention demonstrate immunomodulatory activity and thus the invention further provides a method for treating an inflammatory or autoimmune disorder or a proliferative disorder. In certain embodiments, the inventive compounds are useful for the treatment of rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, urticaria, allergic rhinitis, myasthenia gravis, diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, reperfusion injury, bone metastasis, bone resorption disorders, such as osteoporosis, and cancer.



[0083] As mentioned above, compounds of the invention have been shown to inhibit adhesion molecule expression such as E-selectin and ICAM-1 on the endothelial cell surface induced by stimulation with inflammatory cytokines. Accordingly, compounds of the invention may be useful for the treatment or prophylaxis of diseases caused by expression of adhesion molecules. These diseases include those in which leukocyte trafficking plays a role, notably acute and chronic inflammatory diseases, autoimmune diseases, tumor metastasis, allograft rejection, and reperfusion injury.

[0084] Therefore, in certain embodiments, compounds of the invention may be useful for the treatment of any one or more of the above-mentioned diseases or conditions. In certain exemplary embodiments, compounds of the invention are useful for treating or lessening the severity of disorders selected from reperfusion injury, bone metastasis and/or bone resorption disorders, such as osteoporosis.

[0085] *Reperfusion injury*

[0086] Tissues deprived of blood and oxygen undergo ischemic necrosis or infarction with possible irreversible organ damage. In some circumstances, however, such as during cardiac surgery, it is desirable to interrupt the normal myocardial contractions (cardioplegia) and actually induce ischemia. Such elective or obligatory ischemia occurs in the presence of safeguards such as cardioplegia-induced cardiac arrest and hypothermia. While these safeguards provide considerable myocardial protection, alteration of myocardial energetics (stunning) and poor postoperative ventricular function still remain significant problems.

[0087] Once the flow of blood and oxygen is restored to the organ or tissue (reperfusion), the organ does not immediately return to the normal preischemic state. For example, reperfused postischemic non-necrotic myocardium is poorly contractile and has reduced concentrations of high energy nucleotides, depressed subcellular organelle function and membrane damage that resolves only slowly. Although reperfusion restores oxygen and reverses ischemia, repletion of high energy nucleotides such as adenosine triphosphate (ATP) and reversal of ischemic membrane damage is slow, and contractile function may be profoundly depressed for a long period. Just minutes of ischemia causes loss of myocardial systolic wall thickening for hours. Longer periods of reversible ischemia may depress contractility for days.

[0088] In certain exemplary embodiments, compounds of the invention are useful for treatment of stroke, cardiac, brain and/or renal reperfusion injury.

**[0089]**     *Bone metastasis*

**[0090]**     Although the success rate for curing primary cancers is increasing, metastasis remains a limiting factor in antitumour therapy. Metastasis involves the spread of cancer cells from the primary cancer site to a secondary location elsewhere in the body. A common secondary site for metastasising tumour cells is in the bone. The presence of malignant cells in bone induces metabolic bone disease leading, for example, to bone resorption. The clinical symptoms of bone metastasis such as bone pain are partly linked to bone resorption. In advanced metastatic bone disease, the patient experiences excruciating pain due to pressure of the tumor on surrounding nerves, tissue, and the innervation of the bone and endosteum or periosteum itself. The quality of the patient's life at this point can deteriorate quickly, and the levels of pain become intolerable. In certain embodiments, compounds of the invention are useful for the treatment of bone metastases and/or are useful therapeutic agents for relieving bone pain in patients suffering from bone metastasis.

**[0091]**     *Pharmaceutical Compositions*

**[0092]**     As discussed above this invention provides novel compounds that have biological properties useful for the treatment of inflammatory and proliferative disorders, including, but not limited to rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, urticaria, allergic rhinitis, myasthenia gravis, diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, reperfusion injury, bone metastasis, bone resorption disorders, such as osteoporosis, and cancer.

**[0093]**     Accordingly, in another aspect of the present invention, pharmaceutical compositions are provided, which comprise any one or more of the compounds described herein (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), and optionally comprise a pharmaceutically acceptable carrier. In certain embodiments, a pharmaceutical composition comprising an inventive compound (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), a carrier or diluent and optionally an additional therapeutic agent is provided. In certain embodiments, compositions of the invention optionally further comprise one or more additional therapeutic agents. Alternatively, a compound of this invention may be administered to a patient in need thereof in

combination with the administration of one or more other therapeutic agents. For example, additional therapeutic agents for conjoint administration or inclusion in a pharmaceutical composition with a compound of this invention may be an anti-inflammatory agent (*e.g.*, an agent for the treatment of rheumatoid arthritis or psoriasis) or cytotoxic agent or anticancer agent approved for the treatment of cancer, as discussed in more detail herein, or it may be any one of a number of agents undergoing approval in the Food and Drug Administration that ultimately obtain approval for the treatment of an immune disorder or cancer. It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present invention, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or a prodrug or other adduct or derivative of a compound of this invention which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.

[0094] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds, are well known in the art. For example, S.M. Berge, *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 66: 1-19 (1977), incorporated herein by reference. The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or separately by reacting a free base or free acid function with a suitable reagent, as described generally below. For example, a free base function can be reacted with a suitable acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may, include metal salts such as alkali metal salts, *e.g.* sodium or potassium salts; and alkaline earth metal salts, *e.g.* calcium or magnesium salts. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the

art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, harnisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

**[0095]** Additionally, as used herein, the term “pharmaceutically acceptable ester” refers to esters that hydrolyze *in vivo* and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

**[0096]** Furthermore, the term “pharmaceutically acceptable prodrugs” as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term “prodrug” refers to compounds that are rapidly transformed *in vivo* to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

[0097] As described above, the pharmaceutical compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

[0098] *Uses and Formulations of Compounds of the Invention*

[0099] As described in more detail herein, in general, the present invention provides compounds useful for the treatment of inflammatory or autoimmune disorders and the treatment of proliferative disorders. Without wishing to be bound by any particular theory, more generally, the compounds of the invention have been shown to inhibit adhesion molecule expression such as E-selectin and ICAM-1 on the endothelial cell surface induced by stimulation with inflammatory cytokines. Such cell surface molecules play a critical role for inflammatory cell

infiltration and cell-cell interactions within inflammatory and immune responses. The compounds also reduce activation of the transcriptional factor NF- $\kappa$ B and inhibit the transcriptional activation in inflammatory cytokine signaling pathways, which regulates many genes such as IL-1 $\alpha$  and TNF  $\alpha$  involved in the pathology of several inflammatory diseases. More generally, the identification of NF- $\kappa$ B as a key player in the pathogenesis of inflammation suggest that NF- $\kappa$ B targeted therapeutics may be effective in inflammatory and immune disorders (see, generally, NF- $\kappa$ B in Defense and Disease, *J. Clin. Investig.* 2001, 107, 7).

**[0100]** As detailed in the exemplification herein in assays to determine the ability of compounds to inhibit cytokine-induced adhesion molecule expression by endothelial cells, certain inventive compounds, (generally where one occurrence of R<sub>3</sub> is hydrogen, and the other occurrence of R<sub>3</sub> is a moiety as described generally herein) exhibited IC<sub>50</sub> values (E-Selectin and ICAM-1) less than 1  $\mu$ M. In other embodiments, exemplary compounds exhibited IC<sub>50</sub> values less than 10  $\mu$ M.

**[0101]** As discussed above, compounds of the invention exhibit immunomodulatory activity and exhibit activity for the inhibition of tumor cell growth. As such, compounds of the invention are particularly useful for the treatment of diseases and disorders including, but not limited to, rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, urticaria, allergic rhinitis, myasthenia gravis, diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, reperfusion injury, bone metastasis, bone resorption disorders, such as osteoporosis, and cancer.

**[0102]** Thus, as described above, in another aspect of the invention, methods for the treatment of inflammatory or autoimmune and proliferative disorders are provided comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutical composition thereof, as described herein, to a subject in need thereof. In certain embodiments, the inventive compounds are useful for the treatment of rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, urticaria, allergic rhinitis, myasthenia gravis,

diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, reperfusion injury, bone metastasis, bone resorption disorders, such as osteoporosis, and cancer.

[0103] In certain embodiments, there is provided a method for treating or lessening the severity of reperfusion injury comprising administering a therapeutically effective amount of an inventive compound (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), or pharmaceutical composition thereof, to a subject (including, but not limited to a human or animal) in need of it.

[0104] In certain embodiments, there is provided a method for treating or lessening the severity of a bone resorption disorder, such as osteoporosis, comprising administering a therapeutically effective amount of an inventive compound (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), or pharmaceutical composition thereof, to a subject (including, but not limited to a human or animal) in need of it.

[0105] In certain embodiments, there is provided a method for treating or lessening the severity of bone metastasis comprising administering a therapeutically effective amount of an inventive compound (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), or pharmaceutical composition thereof, to a subject (including, but not limited to a human or animal) in need of it.

[0106] In certain embodiments, the method involves the administration of a therapeutically effective amount of a compound of the invention (or a prodrug, pharmaceutically acceptable salt or other pharmaceutically acceptable derivative thereof), or pharmaceutical composition thereof, and an additional therapeutic agent.

[0107] It will be appreciated that the compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for the treatment of inflammatory or autoimmune and proliferative disorders. Thus, the expression "effective amount" as used herein, refers to a sufficient amount of agent to kill or inhibit the growth of tumor cells, or refers to a sufficient amount to reduce the effects of an inflammatory or autoimmune response or disorder. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular therapeutic agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein

refers to a physically discrete unit of therapeutic agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts (see, for example, Goodman and Gilman's, "The Pharmacological Basis of Therapeutics", Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173, 2001, which is incorporated herein by reference in its entirety).

**[0108]** Furthermore, after formulation with an appropriate pharmaceutically acceptable carrier in a desired dosage, the pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered at dosage levels of about 0.001 mg/kg to about 50 mg/kg, from about 0.01 mg/kg to about 25 mg/kg, or from about 0.1 mg/kg to about 10 mg/kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect. It will also be appreciated that dosages smaller than 0.001 mg/kg or greater than 50 mg/kg (for example 50-100 mg/kg) can be administered to a subject. In certain embodiments, compounds are administered orally or parenterally.

**[0109]** Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol,



tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0110] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0111] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0112] In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension or crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include (poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

[0113] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are

solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

**[0114]** Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

**[0115]** Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

**[0116]** The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as

sucrose, lactose and starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, *e.g.*, tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

[0117] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0118] It will also be appreciated that the compounds and pharmaceutical compositions of the present invention can be formulated and employed in combination therapies, that is, the compounds and pharmaceutical compositions can be formulated with or administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another anti-inflammatory agent or anticancer agent), or they may achieve different effects (*e.g.*, control of any adverse effects).

[0119] For example, other therapies or anticancer agents that may be used in combination with the inventive compounds of the present invention include surgery, radiotherapy (in but a

few examples,  $\gamma$ -radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes, to name a few), endocrine therapy, biologic response modifiers (interferons, interleukins, and tumor necrosis factor (TNF) to name a few), hyperthermia and cryotherapy, agents to attenuate any adverse effects (*e.g.*, antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, alkylating drugs (mechlorethamine, chlorambucil, Cyclophosphamide, Melphalan, Ifosfamide), antimetabolites (Methotrexate), purine antagonists and pyrimidine antagonists (6-Mercaptopurine, 5-Fluorouracil, Cytarabine, Gemcitabine), spindle poisons (Vinblastine, Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan, Topotecan), antibiotics (Doxorubicin, Bleomycin, Mitomycin), nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase), and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol), to name a few. For a more comprehensive discussion of updated cancer therapies see, The Merck Manual, Seventeenth Ed. 1999, the entire contents of which are hereby incorporated by reference. See also the National Cancer Institute (NCI) website ([www.nci.nih.gov](http://www.nci.nih.gov)) and the Food and Drug Administration (FDA) website for a list of the FDA approved oncology drugs ([www.fda.gov/cder/cancer/druglistframe](http://www.fda.gov/cder/cancer/druglistframe)—See Appendix A).

**[0120]** In certain embodiments, the pharmaceutical compositions of the present invention further comprise one or more additional therapeutically active ingredients (*e.g.*, chemotherapeutic and/or palliative). For purposes of the invention, the term “*Palliative*” refers to treatment that is focused on the relief of symptoms of a disease and/or side effects of a therapeutic regimen, but is not curative. For example, palliative treatment encompasses painkillers, anti-nausea medications and anti-sickness drugs. In addition, chemotherapy, radiotherapy and surgery can all be used palliatively (that is, to reduce symptoms without going for cure; *e.g.*, for shrinking tumors and reducing pressure, bleeding, pain and other symptoms of cancer).

#### TREATMENT KITS

**[0121]** In other embodiments, the present invention relates to a kit for conveniently and effectively carrying out the methods in accordance with the present invention. In general, the pharmaceutical pack or kit comprises one or more containers filled with one or more of the

ingredients of the pharmaceutical compositions of the invention. Such kits are especially suited for the delivery of solid oral forms such as tablets or capsules. Such a kit preferably includes a number of unit dosages, and may also include a card having the dosages oriented in the order of their intended use. If desired, a memory aid can be provided, for example in the form of numbers, letters, or other markings or with a calendar insert, designating the days in the treatment schedule in which the dosages can be administered. Alternatively, placebo dosages, or calcium dietary supplements, either in a form similar to or distinct from the dosages of the pharmaceutical compositions, can be included to provide a kit in which a dosage is taken every day. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

#### **EQUIVALENTS**

**[0122]** The representative examples that follow are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. It should further be appreciated that the contents of those cited references are incorporated herein by reference to help illustrate the state of the art.

**[0123]** The following examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and the equivalents thereof.

#### **EXEMPLIFICATION**

**[0124]** The compounds of this invention and their preparation can be understood further by the examples that illustrate some of the processes by which these compounds are prepared or used. It will be appreciated, however, that these examples do not limit the invention. Variations of the invention, now known or further developed, are considered to fall within the scope of the present invention as described herein and as hereinafter claimed.








[0125] According to the present invention, any available techniques can be used to make or prepare the inventive compounds or compositions including them. For example, a variety of solution phase synthetic methods such as those discussed in detail below may be used. Alternatively or additionally, the inventive compounds may be prepared using any of a variety of combinatorial techniques, parallel synthesis and/or solid phase synthetic methods known in the art.







[0126] It will be appreciated as described below, that a variety of inventive compounds can be synthesized according to the methods described herein. The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Company (Milwaukee, WI), Bachem (Torrance, CA), Sigma (St. Louis, MO), or are prepared by methods well known to a person of ordinary skill in the art following procedures described in such references as Fieser and Fieser 1991, "Reagents for Organic Synthesis", vols 1-17, John Wiley and Sons, New York, NY, 1991; Rodd 1989 "Chemistry of Carbon Compounds", vols. 1-5 and supps, Elsevier Science Publishers, 1989; "Organic Reactions", vols 1-40, John Wiley and Sons, New York, NY, 1991; March 2001, "Advanced Organic Chemistry", 5th ed. John Wiley and Sons, New York, NY; and Larock 1989, "Comprehensive Organic Transformations", VCH Publishers. These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to a person of ordinary skill in the art having regard to this disclosure.

[0127] The starting materials, intermediates, and compounds of this invention may be isolated and purified using conventional techniques, including filtration, distillation, crystallization, chromatography, and the like. They may be characterized using conventional methods, including physical constants and spectral data.

[0128] *1) Exemplary Compounds*

[0129] Certain exemplary compounds of the invention are listed below and are referred to by compound number as indicated.

	ER-#	Structure
1	805600 (IC375)	
2	805894 (IC 400)	
3	806006	
4	805985 (IC403)	
5	805984	
6	806002	
7	805969	

8	805971	
9	805996	
10	805639 (IC 397)	
11	805895 (IC 405)	
12	806007	
13	805976	











14	805975	
15	805999	
16	806011	
17	805970	
18	805972	
19	805997	









20	806010	
21	806014	
22	806094	
23	806095	
24	806097	
25	806107	









26	806123	
27	806136	
28	806181	
29	806221	
30	806220	
31	806224	
32	806228	
33	806276	

34	806275	
35	806274	
36	806273	
37	806286	
38	806287	
39	806311	
40	806317	
41	806320	

42	806329	
43	806333	
45	806336	
46	806355	
47	806358	
48	806359	
49	806363	
50	806362	

51	806361	
52	806368	
53	806372	
54	806373	
55	806374	
56	806375	
57	806383	
58	806393	

59	806401	
60	806402	
61	806404	
62	806417	
63	806419	
64	806420	
65	806421	
66	806432	









67	806435	
68	806437	
69	806569	
70	806609	
71	806610	
72	806644	
73	806645	
74	806646	




















75	806647	
76	806653	
77	806671	
78	806781	
79	806790	
80	806796	
81	806820	









82	806839	
83	806840	
84	806841	
85	806842	
86	806843	
87	806844	
88	806860	
89	806874	

90	806875	
91	806878	
92	806899	
93	806900	
94	806901	
95	806902	
96	806903	
97	806904	

98	806905	
99	806987	
100	807014	
101	807015	
102	807139	
103	807140	
104	807183	
105	807240	

106	807313	
107	807377	
108	807392	
109	807400	
110	807401	 Trans racemic
111	807399	 Cis racemic
112	807447	
113	807448	









114	807449	
115	807450	
116	807451	
117	807452	
118	807453	
119	807454	
120	807457	
121	807458	
122	807459	

123	807460	
124	807462	
125	807463	
126	807464	
127	807465	
128	807466	
129	807467	
130	807469	









131	807496	
132	807497	
133	807498	
134	807505	
135	807506	
136	807528	
137	807531	
138	807532	
139	807543	











140	807544	
141	807546	
142	807548	
143	807549	
144	807550	
145	807562	
146	807571	
147	807573	

148	807584	
149	807585	
150	807586	
151	807587	
152	807636	
153	807649	
154	807660	
155	807662	









156	807663	
157	807703	
158	807704	
159	807748	
160	807749	
161	807750	
162	807751	
163	807754	

164	807758	
165	807759	
166	807762	
167	807779	
168	807787	
169	807788	
170	807789	
171	807790	









172	807794	
173	807835	
174	807836	
175	807837	
176	807862	
177	807865	
178	807876	
179	807892	









180	807920	
181	807930	
182	807931	
183	807952	
184	807956	
185	807962	
186	807976	










187	807977	
188	807978	
189	807980	
190	808009	
191	808028	
192	808036	
193	808039	










194	808040	
195	808041	
196	808069	
197	808078	
198	808079	
199	808080	
200	808081	
201	808082	

















202	808083	
203	808084	
204	808085	
205	808086	
206	808101	
207	808102	
208	808103	
209	808107	

210	808128	
211	808151	
212	808152	
213	808153	
214	808160	
215	808164	
216	808247	
217	808254	










218	808255	
219	808256	
220	808257	
221	808259	
222	808260	
223	808261	
224	808262	
225	808266	
226	808268	

227	808269	
228	808281	
229	808283	
230	808284	
231	808285	
232	808286	
233	808287	
234	808288	
235	808289	

236	808290	
237	808291	
238	808310	
239	808311	
240	808312	
241	808313	









242	808319	
243	808322	
244	808346	
245	808347	
246	808355	
247	808356	
248	808361	
249	808362	

250	808363	
251	808364	
252	808365	
253	808370	
254	808371	
255	808372	
256	808385	
257	808386	








258	808387	
259	808388	
260	808469	
261	808470	
262	808473	
263	808496	
264	808497	
265	808498	
266	808499	












267	808500	
268	808501	
269	808513	
270	808514	
271	808541	
272	808542	
273	808543	
274	808544	










275	808548	
276	808571	
277	808576	
278	808600	
278	808617	
279	808620	
280	808622	
281	808623	



291	808660	
292	808661	
293	808663	
294	808665	
295	808672	
296	808673	
297	808675	

298	808691	
299	808692	
300	808702	
301	808703	
302	808704	
303	808705	
304	808711	
305	808712	
306	808713	











307	808714	
308	808717	
309	808719	 chiral
310	808720	
311	808833	
312	808834	
313	808835	
314	808836	
315	808849	










316	808983	
317	808984	
318	809047	
319	809187	
320	809189	
321	809190	
322	809191	
323	809192	
324	809193	











325	809196	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
326	809197	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
327	809198	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
328	809199	<p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>
329	809200	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
330	809201	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
331	809202	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
332	809203	<p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>














333	809204	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
334	809205	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
335	809206	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
336	809207	<p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>
337	809208	<p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>
338	809209	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
339	809210	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
340	809211	<p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
341	809212	<p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>

342	809213	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
343	809214	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
344	809215	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
345	809216	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
346	809217	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
347	809218	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
348	809219	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
349	809220	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
350	809221	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
351	809222	 <p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>

352	809223	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
353	809224	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>
354	809225	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>
355	809226	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
356	809227	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>
357	809228	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>
358	809229	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>
359	809230	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>
360	809231	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>

361	809232	 CF <sub>3</sub> CO <sub>2</sub> H
362	809233	 2 CF <sub>3</sub> CO <sub>2</sub> H
363	809234	 2 CF <sub>3</sub> CO <sub>2</sub> H
364	809235	 CF <sub>3</sub> CO <sub>2</sub> H
365	809236	 CF <sub>3</sub> CO <sub>2</sub> H
366	809237	 CF <sub>3</sub> CO <sub>2</sub> H
367	809238	 CF <sub>3</sub> CO <sub>2</sub> H
368	809251	 CF <sub>3</sub> CO <sub>2</sub> H
369	809252	 CF <sub>3</sub> CO <sub>2</sub> H
370	IC261	 CF <sub>3</sub> CO <sub>2</sub> H

371	IC375	
372	IC380	
373	IC395	
374	IC396	
375	IC400	
376	IC401	
377	IC402	
378	IC403	

		
379	IC404	
380	IC415	
381	IC416	

[0130]        2)        ***Experimental Procedures:***

[0131]        As described above, the present invention provides novel deazapurines having formula (I) as described above and in certain classes and subclasses herein. The synthesis of several exemplary compounds is described in detail below. It will be appreciated that the methods as described herein can be applied to each of the compounds as disclosed herein and equivalents thereof. Additionally, certain reagents and starting materials are well known to those skilled in the art. Although the following examples describe certain exemplary compounds, it will be appreciated that the use of alternate starting materials will readily yield other analogues encompassed by the invention.

[0132]        **General Reaction Procedures:**

[0133]        Unless mentioned specifically, reaction mixtures were stirred using a magnetically driven stirrer bar. An inert atmosphere refers to either dry argon or dry nitrogen.

Reactions were monitored either by thin layer chromatography, or by proton nuclear magnetic resonance, of a suitably worked up sample of the reaction mixture.



**[0134]      General Work Up Procedures:**

**[0135]**      Unless mentioned specifically, reaction mixtures were cooled to room temperature or below then quenched, when necessary, with either water or a saturated aqueous solution of ammonium chloride or sodium bicarbonate. Desired products were extracted by partitioning between water and a suitable water-immiscible solvent (*e.g.* ethyl acetate, dichloromethane, diethyl ether). The desired product containing extracts were washed appropriately with water followed by a saturated solution of brine. On occasions where the product containing extract was deemed to contain residual oxidants, the extract was washed with a 10% solution of sodium sulphite in saturated aqueous sodium bicarbonate solution, prior to the aforementioned washing procedure. On occasions where the product containing extract was deemed to contain residual acids, the extract was washed with saturated aqueous sodium bicarbonate solution, prior to the aforementioned washing procedure (except in those cases where the desired product itself had acidic character). On occasions where the product containing extract was deemed to contain residual bases, the extract was washed with 10% aqueous citric acid solution, prior to the aforementioned washing procedure (except in those cases where the desired product itself had basic character). Post washing, the desired product containing extracts were dried over anhydrous sodium or magnesium sulphate, then filtered. The crude products were then isolated by removal of solvent(s) by rotary evaporation under reduced pressure, at an appropriate temperature (generally less than 45°C).


**[0136]      General Purification Procedures:**

**[0137]**      Unless mentioned specifically, chromatographic purification refers to flash column chromatography on silica gel, using a single solvent or mixed solvent as eluent. Suitably purified desired product containing elutes were combined and concentrated under reduced pressure at an appropriate temperature (generally less than 45°C) to constant mass.

**[0138]      Experimentals for Certain Exemplary Compounds:**




**[0139]** In certain embodiments, compounds 1 and 2 were prepared according to the procedure of Temple, C.; Smithy, B. H.; Montgomery, J. A.; *J Org Chem.* **1973**, 38, 613-5.



**[0140]** Dry HCl (gas) was bubbled through a 2 M solution of nitrile ( $R_2-CN$ ) in ethyl ether containing 1 mole equivalent of ethanol at  $-10\text{ }^{\circ}\text{C}$  for 1-2 hours. After stirring from additional an hour to overnight at room temperature, nitrogen was bubbled through to purge excess HCl gas and ether. The remaining slurry or suspension was filtered, washed with ether three times and then dried under vacuum to give the corresponding ethyl imidate hydrogen chloride.


**[0141]** A mixture of **1** (1 mmol) and the ethyl imidate hydrogen chloride (1.1 mmol) in 5 mL of ethanol was heated at 65-70 °C until reaction was completed (1.5 h to overnight). The mixture was cooled to room temperature, diluted with 20 mL of water, stirred for 30 min., filtered and washed with water. The cake was collected and dried under vacuum to give the desired product **3**.



**[0142]** A solution of **3** (1 mmol) in 2.8 mL of 57% HI (aq., 20 mmol) was heated at reflux until reaction was completed (12 –20 h). The mixture was cooled to 0 °C, slowly diluted




with 5 N NaOH solution (19 mmol) and then with 1 mL of sat. NaHCO<sub>3</sub> to pH~9. The resulting mixture was extracted with either ethyl acetate or ethyl acetate/THF mixture until extraction was completed. The combined extracts was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give the desired product **4** as free form. Washing the product with ethyl acetate resulted in a better purity if necessary in certain cases. The HI mono-salt form of **4** was obtained after cooling the reaction mixture to room temperature, filtration, washing with water and drying the collected yellow solid in high vacuum.



**5**


**[0143]** A mixture of **1** (300 mg, 1.3 mmol) and tetraethyl orthocarbonate (2.6 mmol) in 10 mL of acetic acid was stirred at room temperature overnight and reaction was completed. The reaction mixture was concentrated under reduced vacuum and the residue was diluted with sat. NaHCO<sub>3</sub>, extracted with EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated to give a brownish solid. This solid was dissolved in 24 mL of H<sub>2</sub>O-MeOH (1:1) solution containing 1.2 g of KOH and heated at reflux for 2.5 h. After cooling to room temperature, the mixture was extracted with EtOAc. The extracts was washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (10% MeOH-EtOAc) to give **5** (45 mg, 16%).



**6**


**[0144]** A solution of **1** (203 mg, 0.88 mmol) in trifluoroacetic acid (2 mL) was heated at 70 °C for 12 h, cooled to room temperature, concentrated and the residue was diluted with sat. NaHCO<sub>3</sub> (10 mL) and EtOAc (10 mL). The separated aqueous phase was extracted with 4x10 mL of EtOAc and the combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated

to give a yellow solid. This yellow solid was mixed with 3 mL of polyphosphoric acid, heated at 200 °C for 3 h and cooled to room temperature. The reaction mixture was carefully quenched with sat. NaHCO<sub>3</sub> (80 ml) and extracted with 4x20 mL of EtOAc. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a brownish yellow solid. This solid was dissolved in 5 mL of 57% HI solution and heated at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was carefully poured into sat. NaHCO<sub>3</sub> (60 ml) containing 3 mL of 1 N NaOH and extracted with 4x20 mL of EtOAc. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated and the product was purified by chromatography (50 to 100% EtOAc-hexanes) to give the desired product **6** (132 mg, 46% for 3 steps).



**7**


**[0145]** A mixture of methyl indole-5-carboxylate (27 g, 155 mmol) (or the corresponding 4-, 6- and 7-carboxylate), di-*t*-butyl dicarbonate (40 g, 1.2 eq.), Et<sub>3</sub>N (26 mL, 1.2 eq.) and DMAP (0.1 g, 0.005 eq.) in THF (165 mL) was stirred at room temperature overnight. The reaction mixture was quenched by addition of sat. NaHCO<sub>3</sub> (350 mL). The separated aqueous layer was extracted once with EtOAc. The combined organic phase was concentrated and the product was purified by chromatography (5% and 10% EtOAc-hexanes) to provide **7** (42 g, 100%).




**8**

**[0146]** To a solution of **7** (42 g, 152 mmol) in dichloromethane (400 mL) at -78 °C was added a 1 M solution of DIBAL-H in toluene (460 mL, 3.0 eq.) during 30 min of period. The cooling bath was replaced with -40 °C, the reaction mixture was stirred and warmed to -30 °C and TLC showed reaction was completed. The reaction was quenched with careful addition of MeOH (57 mL, 9.0 eq.) and water (19 mL, 9.0 eq.), diluted with EtOAc (150 mL) and then warmed to rt. The resulting suspension mixture was filtered through celite washing with EtOAc

until the product was no longer detected. The filtrate was concentrated and the product was purified by chromatography (15% and 30% EtOAc-hexanes) to provide **8** (29 g, 75%).




[0147] Methanesulfonyl chloride (10.1 mL, 1.2 eq.) was added to a solution of **8** (27.0 g, 109 mmol, 1.0 eq.) and diisopropylethylamine (57 mL, 3.0 eq.) in dichloromethane (250 mL) at 0 °C during 5 min. After stirring additional 15 min, morpholine (14.3 mL, 1.5 eq. or cyclic or acyclic R'R''NH) was added to the reaction mixture and stirred at room temperature overnight. The mixture was poured into sat. NaHCO<sub>3</sub> (100 mL) and water (20 mL), the separated aqueous phase was extracted with 4x50 mL of EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (15% to 40% EtOAc-hexanes) to provide **9** (34.0 g, 99%).




[0148] Method A: To a solution of diisopropylamine (17.0 mL, 1.2 eq.) in THF (350 mL) at -78 °C was added nBuLi (2.5 M in hexanes, 48.6 mL, 1.2 eq.) over a 15 min period and the reaction mixture was stirred and warmed to room temperature after removing the cooling bath. The reaction mixture was cooled back to -78 °C and a solution of **9** (32 g, 101 mmol) in THF (120 mL) was introduced by cannulation during 15 min. The resulting mixture was stirred and warmed to -20 °C during 15 min and then Bu<sub>3</sub>SnCl (31.5 mL, 1.15 eq.) was introduced. The mixture was stirred and warmed to room temperature and poured into a sat. NH<sub>4</sub>Cl (300 mL). The separated aqueous phase was extracted with 3x100 mL of EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by vacuum chromatography (5% to 50% EtOAc-hexanes) to provide **10** (55 g, 89%).

[0149] Method B: This reaction was also carried out by following the same protocol as that used for the preparation of **15** from **14**.




**11**

**[0150]** Compound **11** was prepared from indole-1-carboxylic acid tert-butyl ester in 86% following the same procedure for the preparation of **10** from **9**.



**12**







**[0151]** Compound **12** was prepared from mono- or di-substituted indole following similar procedures for the preparation of **7** and **10**.














**13**







**[0152]** A mixture of **4** (0.4 mmol, 1.0 eq., or **2** or **5** or **6**), **10** (1.6 eq., or **11** or **12**) and  $[(C_6H_5)_3P]_4Pd$  (0.1 eq.) in degassed DMF (1 mL) under nitrogen with or without  $K_2CO_3$  (1.0 eq.) was heated at 110 °C for 18-28 h, cooled to room temperature and concentrated under high vacuum. The residue was diluted with sat.  $NaHCO_3$  (10 mL) and EtOAc. The separated aqueous phase was extracted with EtOAc multiple times until there was no product detected. The combined organic phase was dried over  $Na_2SO_4$ , filtered and concentrated. The product was purified by chromatography (5% or 10% MeOH-EtOAc) to give the desired <sup>dr</sup> product **13**.

Compound # (ER # or IC #)	Structure of 13	MS (ES) or/and <sup>1</sup> H NMR



<b>IC 400</b>		<sup>1</sup> H NMR
<b>806014</b>		287.3 (M-H) <sup>-</sup>
<b>806006</b>		316.3 (M-H) <sup>-</sup>
<b>805985</b>		278.3 (M+H) <sup>+</sup>
<b>805984</b>		292.3 (M+H) <sup>+</sup>
<b>806002</b>		306.3 (M+H) <sup>+</sup>


805969		326.3 (M+H) <sup>+</sup>
805971		354.3 (M+H) <sup>+</sup>
805996		<sup>1</sup> H NMR
805639 (IC 379)		<sup>1</sup> H NMR
805895 (IC 405)		<sup>1</sup> H NMR

806007		425.2 (M-H) <sup>-</sup>
805976		<sup>1</sup> H NMR
805975		<sup>1</sup> H NMR
805999		<sup>1</sup> H NMR
806011		393.3 (M+H) <sup>+</sup>
805970		<sup>1</sup> H NMR

805972		453.3 (M+H) <sup>+</sup>
805997		469.2 (M-H) <sup>-</sup>
806010		455.3 (M+H) <sup>+</sup>
809189		<sup>1</sup> H NMR
809190		<sup>1</sup> H NMR
809191		<sup>1</sup> H NMR




<b>809192</b>		<sup>1</sup> H NMR
<b>809193</b>		<sup>1</sup> H NMR



**14**


[0153] To a mixture of **8** (5-hydroxymethyl-indole-1-carboxylic acid *tert*-butylester as an example, 24.4 g, 98.8 mmol), Et<sub>3</sub>N (41 mL, 3 eq.) and DMAP (1.2 g, 0.1 eq.) in dichloromethane (185 mL) was added TBSCl (23.1 g, 1.5 eq.) at room temperature and the resulting mixture was stirred overnight. The reaction was quenched with the addition of sat. NaHCO<sub>3</sub> (200 mL) and the separated aqueous layer was extracted with 3x50 mL dichloromethane. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by vacuum chromatography (3% EtOAc-hexanes) to provide **14** (5-*tert*-butyl-dimethyl-silyloxymethyl)-indole-1-carboxylic acid *tert*-butyl ester) as a colorless oil (33.9 g, 95%).



**15**


[0154] To a solution of **14** (5-*tert*-butyl-dimethyl-silyloxymethyl-indole-1-carboxylic acid *tert*-butyl ester as an example, 33.5 g, 92.7 mmol) in THF (650 mL) below -72 °C was added *t*BuLi (63 mL, 1.7 M in pentane, 1.2 eq.) dropwise over a period of 45 min and stirring was continued for an additional 40 min. The resulting brown solution was briefly warmed to -60 °C and then cooled back to below -72 °C. Bu<sub>3</sub>SnCl (31.6 mL, 1.3 eq.) was then introduced to the reaction mixture and stirred at -40 °C for 15 min. The reaction was quenched at -35 °C with sat. NaHCO<sub>3</sub> (250 mL) and the separated aqueous layer was extracted with 3x150 mL EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was

purified by vacuum chromatography (hexanes) to provide **15** (5-(*tert*-butyl-dimethyl-silanyloxymethyl)-2-tributylstannyl-indole-1-carboxylic acid *tert*-butyl ester) as a colorless oil (60.6 g, 100%).



**16**

[0155] A solution of **15** (5-(*tert*-butyl-dimethyl-silanyloxymethyl)-2-tributylstannyl-indole-1-carboxylic acid *tert*-butyl ester as an example, 60.6 g, 3.0 eq.) in DMF (100 mL) was added in four portions during 24 h period to a solution of **4** ( $R_2=Me$ , 8.51 g, 31.0 mmol),  $Pd(Ph_3P)_4$  (3.2 g, 0.09 eq.) and  $Et_3N$  (26 mL, 3.0 eq.) in DMF (100 mL) with or without  $K_2CO_3$  (1.0 eq.) at 110 °C under nitrogen atmosphere. The resulting mixture was stirred for 20 h, cooled to room temperature and concentrated. The residue was diluted with sat.  $NaHCO_3$  (300 mL) and EtOAc (300 mL), filtered and washed with EtOAc to get rid of dark gray sludge. The separated aqueous phase from the filtrate was extracted with 6x200 mL EtOAc until no desired product detected by TLC. The combined organic phase was dried over  $Na_2SO_4$ , filtered and concentrated. The residue was diluted with EtOAc and the resulting suspension was filtered, washed with EtOAc and 2xMeOH to give **16** (4.27 g). The filtrate was concentrated and the residual product was purified by chromatography (0 to 5% MeOH-EtOAc) to give additional **16** (2.59 g). The products were combined to give **16** (7-[5-(*tert*-butyl-dimethyl-silanyloxymethyl)-1*H*-indol-2-yl]-2-methyl-3*H*-imidazo[4,5-*b*]pyridin-5-ylamine) as a greenish gray solid (6.86 g, 54%).




**17**

[0156] A solution of tBuOK in THF (1.66 M, 96.3 mL, 9.5 eq.) was added to a mixture of **16** (7-[5-(*tert*-butyl-dimethyl-silanyloxymethyl)-1*H*-indol-2-yl]-2-methyl-3*H*-imidazo[4,5-*b*]pyridin-5-ylamine as an example, 6.86 g, 16.8 mmol) and di-*tert*-butyl dicarbonate (39 mL, 10 eq.) in THF (1.1 L) at below -28 °C during 40 min period. After stirring for 10 min, the reaction was quenched by addition of sat. NaHCO<sub>3</sub> (300 mL) and warmed to room temperature. The separated aqueous layer was extracted by 3x150 mL of EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by vacuum chromatography (10 to 20% EtOAc/hexanes) to provide a di-Boc-protected intermediate.

[0157] The di-Boc-protected intermediate was then dissolved in 55 mL THF containing Et<sub>3</sub>N (55 mL), DIBOC (22.5 g, 6.0 eq.) and DMAP (0.21 g, 0.1 eq.) and heated at 65 °C for 5 h. After cooling to room temperature, the mixture was concentrated and the product was purified by vacuum chromatography (10% EtOAc-hexanes) to provide tetra-Boc-protected intermediate.


[0158] The tetra-Boc-protected intermediate was then dissolved in a solution of HF/pyridine in THF (0.89 M, 5.3 eq., HF/pyridine solution was prepared by mixing of 10 g of 70% HF/pyridine, 52.5 mL of pyridine and 330 mL of THF) and stirred at room temperature for 40 h. The reaction mixture was then carefully quenched with sat. NaHCO<sub>3</sub> (250 mL) and the separated aqueous layer was extracted by 3x50 mL of EtOAc. The combined organic phase was washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by vacuum chromatography (10 to 50% EtOAc-hexanes) to provide **17** (5-di-(*tert*-butoxycarbonyl)amino-7-(1-*tert*-butoxycarbonyl-5-hydroxymethyl-1*H*-indol-2-yl)-2-methyl-imidazo[4,5-*b*]pyridine-3-carboxylic acid *tert*-butyl ester, 5.64 g, 48% for three steps) as a light yellow solid.



**18**


[0159] Methylsulfonylchloride (0.14 mL, 1.5 eq.) was added to a mixture of **17** (5-di-(*tert*-butoxycarbonyl)amino-7-(1-*tert*-butoxycarbonyl-5-hydroxymethyl-1*H*-indol-2-yl)-2-methyl-imidazo[4,5-*b*]pyridine-3-carboxylic acid *tert*-butyl ester as an example, 830 mg, 1.2

mmol) and diisopropylethylamine (2.08 mL, 10 eq.) in dichloromethane (10 mL) at 0 °C and the resulting mixture was stirred and warmed to room temperature. After stirring for 7 h at room temperature, the mixture was kept at 0 °C for two days, warmed to room temperature and concentrated to half of its volume. The product was then purified by chromatography (20% to 30% EtOAc/hexanes) to give **18** (5-di-(*tert*-butoxycarbonyl)amino-7-(1-*tert*-butoxycarbonyl-5-chloromethyl-1*H*-indol-2-yl)-2-methyl-imidazo[4,5-*b*]pyridine-3-carboxylic acid *tert*-butyl ester, 770 mg, 90%).



**19**


[0160] A mixture of **17** (5-di-(*tert*-butoxycarbonyl)amino-7-(1-*tert*-butoxycarbonyl-5-hydroxymethyl-1*H*-indol-2-yl)-2-methyl-imidazo[4,5-*b*]pyridine-3-carboxylic acid *tert*-butyl ester as an example, 122 mg, 0.18 mmol) and Dess-Martin periodinane (223 mg, 3.0 eq.) in dichloromethane (4 mL) was stirred at room temperature for 1 h. The resulting mixture was diluted with diethyl ether (60 mL), stirred for 20 min and filtered through celite washing with diethyl ether. The filtrate was washed with sat. NaHCO<sub>3</sub> (20 mL) containing Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (500 mg) and the aqueous phase was back extracted with 2x25 mL diethyl ether. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (10 to 30% EtOAc-hexanes) to provide **19** (5-di-(*tert*-butoxycarbonyl)amino-7-(1-*tert*-butoxycarbonyl-5-formyl-1*H*-indol-2-yl)-2-methyl-imidazo[4,5-*b*]pyridine-3-carboxylic acid *tert*-butyl ester, 117 mg, 96%).




**20**

[0161] A solution of KMnO<sub>4</sub> (436 mg, 2 eq.) and KH<sub>2</sub>PO<sub>4</sub> (563 mg, 3 eq.) in water (15 mL) was added to a solution of **19** (5-di-(*tert*-butoxycarbonyl)amino-7-(1-*tert*-butoxycarbonyl-5-


formyl-1*H*-indol-2-yl)-2-methyl-imidazo[4,5-*b*]pyridine-3-carboxylic acid *tert*-butyl ester as an example, 958 mg, 1.38 mmol) in *t*BuOH (10 mL) at room temperature during 3 min and the resulting mixture was stirred for 30 min. The mixture was then diluted with EtOAc (20 mL), filtered through celite washing with EtOAc. The filtrate was diluted with brine (60 mL), water (40 mL) and EtOAc (200 mL). The separated aqueous phase was extracted with 3x30 mL of EtOAc. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (30 to 100% EtOAc/hexanes) to provide **20** (2-(3-*tert*-butylcarbonyl-5-di-(*tert*-butylcarbonyl)amino-2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-indole-1,5-carboxylic acid 1-*tert*-butyl ester, 678 mg, 69%).




[0162] A mixture of (mono- or di-) substituted benzyl chloride (or bromide) or bromomethylnaphthalene or chloromethyl pyridine hydrochloride (20 mmol) and methylamine (22 mL, 40% in water, 10 eq.) in MeOH (18 mL) was stirred at room temperature for 1-5 days until reaction was completed. After concentration, the reaction mixture was diluted with sat. NaHCO<sub>3</sub> (50 mL), extracted with EtAOc until there was no product detected. The combine extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated to give the product **21**.



[0163] Amines **22-26** were prepared following a modified procedure disclosed in published PCT application number WO 01/00610 A1.



[0164] Methanesulfonyl chloride (0.80 mL, 1.2 eq.) was added to a solution of 2-(ethyl-phenyl-amino)-ethanol (1.43 g, 8.65 mmol) and diisopropylethylamine (3.0 mL, 2.0 eq.) in dichloromethane (10 mL) at 0 °C and the resulting mixture was stirred for 15 min. A solution of ammonia (20 mL, 2 M in MeOH) was then introduced and the resulting mixture was stirred at room temperature for five days and concentrated. The residue was diluted with a solution of HCl (7 mL, 1 N) and washed with 3xEtOAc. The aqueous phase was treated with a solution of NaOH (15 mL, 1 N) and extracted once with EtOAc. The extract was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated to give the product **27**.



**28**


[0165] To a solution of 2-benzyloxy-propane-1,3-diol (5.0 g, 27.4 mmol) in 5:1 THF-DMF (200 mL) at 0 °C was added NaH (1.5 g, 2.3 eq.) followed by methyl iodide (5.1 mL, 3.0 eq.). The resulting white slurry mixture was stirred at room temperature over weekend. The reaction mixture was quenched with sat. NH<sub>4</sub>Cl, extracted with EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (50% EtOAc/hexanes) to give (2-methoxy-1-methoxymethyl-2-ethoxymethyl)-benzene (5.6 g, 97%).

[0166] A mixture of (2-methoxy-1-methoxymethyl-2-ethoxymethyl)-benzene (5.5g) and Pd(OH)<sub>2</sub> (0.4 g) in MeOH (150 mL) was stirred at room temperature under hydrogen gas until reaction was completed. The reaction mixture was filtered and concentrated to give 1,3-dimethoxy-propan-2-ol (3.0 g, 96%).

[0167] Methanesulfonyl chloride (0.61 mL, 2.0 eq.) was added to a solution of 1,3-dimethoxy-propan-2-ol (0.50 g, 4.14 mmol) and triethylamine (2.3 mL, 4.0 eq.) in dichloromethane (2 mL) at 0 °C and the resulting mixture was stirred for 15 min. The reaction was quenched by sat. NaHCO<sub>3</sub> and the mixture was extracted with EtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue and NaN<sub>3</sub> (0.80 g, 3.0 eq.) was dissolved in DMSO (10 mL) and heated at 90 °C over weekend. After cooling to room temperature, the mixture was diluted with sat. NaHCO<sub>3</sub> and extracted with diethyl ether. The

combined extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated to give azide intermediate (320 mg, 48%).

[0168] A mixture of the azide intermediate (320 mg) and  $\text{Pd}(\text{OH})_2$  in MeOH (15 mL) was stirred at room temperature under hydrogen gas for 1 h. The reaction mixture was filtered and concentrated to give **28** (150 mg, 63%).



**29**

[0169] A mixture of ethyl-phenyl-amine (4.15 mL, 33 mmol), allyl bromide (4.3 mL, 1.5 eq.) and  $\text{K}_2\text{CO}_3$  (9.1 g, 2.0 eq.) in acetone (50 mL) was heated at reflux for overnight. After cooling to room temperature, the reaction mixture was diluted with water (50 mL) and EtOAc (100 mL). The separated organic phase was dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated and the product was purified by chromatography (10% EtOAc/hexanes) to give allyl-ethyl-phenyl-amine (5.32 g, 100%).

[0170] A solution of  $\text{OsO}_4$  (7.8 mL, 0.1 M in water, 0.03 eq.) was added to a mixture of allyl-ethyl-phenyl-amine (4.10 g, 25.3 mmol) and NMO (5.92 g, 2.0 eq.) in 9:1 acetone-water (40 mL) at room temperature and the resulting mixture was stirred overnight. The mixture was diluted with sat.  $\text{NaHCO}_3$  (80 mL), sat.  $\text{Na}_2\text{S}_2\text{O}_3$  (20 mL) and 1:1  $\text{Et}_2\text{O}$ -hexanes (100 mL). The separated aqueous phase was extracted with 2x30 mL of EtOAc and the combined organic phase was dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated and the product was purified by chromatography (30% EtOAc-hexanes) to give 3-(ethyl-phenyl-amino)-propane-1,2-diol (4.25 g, 86%).


[0171] Methanesulfonyl chloride (2.5 mL, 1.5 eq.) was added to a solution 3-(ethyl-phenyl-amino)-propane-1,2-diol (4.22 g, 21.6 mmol) and triethylamine (9.03 mL, 3.0 eq.) in dichloromethane (20 mL) at  $-30$  to  $-35^\circ\text{C}$  and the resulting mixture was stirred and warmed to  $0^\circ\text{C}$ . The reaction was quenched by sat.  $\text{NaHCO}_3$  (30 mL) and the separated aqueous phase was extracted with 2x20 mL  $\text{CH}_2\text{Cl}_2$  and 20 mL EtOAc. The combined extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The residue was dissolved in MeOH (30 mL) and treated

with NaOMe (2.3 g, 2.0 eq.) at 65-70 °C for 3 h. After cooling to room temperature, the mixture was diluted with sat. NaHCO<sub>3</sub> (50 mL) and extracted with 3x30 mL of EtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated and the product was purified by chromatography (10% EtOAc/hexanes) to give ethyl-oxiranylmethyl-phenyl-amine (1.72 g, 45%).

[0172] A solution of ethyl-oxiranylmethyl-phenyl-amine (1.72 g, 9.65 mmol) and NaOMe (1.04 g, 2.0 eq.) in MeOH (8 mL) was heated at reflux for over weekend. After cooling to room temperature, the mixture was diluted with sat. NaHCO<sub>3</sub> (20 mL) and extracted with 3x20 mL of EtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated and the product was purified by chromatography (30% EtOAc-hexanes) to give 1-(ethyl-phenyl-amino)-3-methoxy-propan-2-ol (1.95 g, 97%).

[0173] A solution of 1-(ethyl-phenyl-amino)-3-methoxy-propan-2-ol (1.95 g, 9.32 mmol) and NMO (2.18 g, 2.0 eq.) in dichloromethane (15 mL) was treated with TPAP (150 mg, 0.05 eq.) at room temperature until reaction was completed. The reaction mixture was diluted with sat. NaHCO<sub>3</sub> (50 mL) and extracted with 3x30 mL EtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated and the product was purified by chromatography (10 to 15% EtOAc-hexanes) to give 1-(ethyl-phenyl-amino)-3-methoxy-propan-2-one (0.98 mg, 51%).


[0174] A mixture of 1-(ethyl-phenyl-amino)-3-methoxy-propan-2-one (17 mg, 0.08 mmol), hydroxylamine hydrochloride (30 mg) and pyridine (0.3 mL) in MeOH (0.4 mL) was stirred at room temperature for 1.5 h. The reaction mixture was diluted with sat. NaHCO<sub>3</sub> and extracted with 3xEtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was dissolved in THF (0.8 mL) and treated with lithium aluminum hydride (0.3 mL, 1 M in THF) at room temperature for overnight. Work-up and purification by chromatography (5:95 ratio of 2 M NH<sub>3</sub> in MeOH:CH<sub>2</sub>Cl<sub>2</sub>) gave **29** as light yellow oil.




**30**



[0175] Compound **30** was prepared from 3-phenoxy-propane-1,2-diol in 21% overall yield following the same procedures for the preparation of **29** from 3-(ethyl-phenyl-amino)-propane-1,2-diol.




**31**




**32**

[0176] A mixture of 3-(bromo-propyl)-benzene or bromomethyl-cyclohexane (1 M, 1.0 eq.) in MeOH and 40% MeNH<sub>2</sub> in water (60 eq.) was stirred at room temperature or at 45 °C until reaction was completed. After cooling to room temperature, the mixture was concentrated and the residue was diluted with saturated NaHCO<sub>3</sub> and extracted with 3xCH<sub>2</sub>Cl<sub>2</sub> (or/and 3xEtOAc). The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give **31** or **32**.




**33**


[0177] Methanesulfonylchloride (0.8 mL, 1.0 eq.) was added to a mixture of cyclopentyl-methanol (1.1 mL, 1.0 eq.) and ethyldiisopropylamine (3.9 mL, 10 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at 0 °C and the resulting mixture was stirred and warmed to room temperature. After addition of saturated NaHCO<sub>3</sub>, the separated aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the combined organic layer was concentrated to give crude mesylate intermediate. This mesylate was then treated with MeNH<sub>2</sub> following the same procedure for the preparation of **31/32** to give **33**.



**34**



**35**




**36**

[0178] A solution of TiCl<sub>4</sub> in CH<sub>2</sub>Cl<sub>2</sub> (1 M, 1.56 mmol) was added to a mixture of 1,2-diphenyl-ethanone (307 mg, 1.56 mmol), Et<sub>3</sub>N (655 μL) and methylamine (1.02 mL) in THF (5 mL) at 0 °C. After stirring 1.5 h, a solution of NaBH<sub>4</sub> (280 mg, 37.8 mmol) in MeOH (8 mL) was added and the resulting mixture was stirred for 2 h. A saturated Na<sub>2</sub>CO<sub>3</sub> was then added and


the reaction mixture was stored in freezer overnight. After thawing, the organic layer was removed and the aqueous phase was extracted with 3xCH<sub>2</sub>Cl<sub>2</sub>. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. Purification by preparative thin layer chromatography (80% EtOAc/hexanes) afforded **34** (195 mg, 59%).

[0179] Compounds **35** and **36** were prepared in a similar manner from 2-methoxy-1-phenyl-ethanone and cycloheptanone, respectively.



**39**


[0180] To a solution of Boc-nortropinone (0.5 g, 2.2 mmol, 1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added TFA (10 mL). The reaction mixture was stirred for 2 hours and then was concentrated. After addition of EtOAc and saturated NaHCO<sub>3</sub>, the reaction mixture was extracted with 3xEtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give **37** (0.25 g).



**38**

[0181] To a solution of 2,5-dihydro-pyrrole-1-carboxylic acid phenyl ester (2 g, 10 mmol, 1.0 eq.) in Acetone/water (9:1, 20 mL) was added OsO<sub>4</sub> (4% in water, 1 mL) and NMO (2.3 g, 20 mmol, 2 eq.). The mixture was stirred at room temperature overnight, concentrated to remove most of the Acetone, poured into saturated NaHCO<sub>3</sub> and extracted with 3xEtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude mixture was purified by silica chromatography (70% to 90% EtOAc-Hexanes) to give 3,4-dihydroxy-pyrrolidine-1-carboxylic acid phenyl ester (2.04g, 88%).

[0182] To a solution of 3,4-dihydroxy-pyrrolidine-1-carboxylic acid phenyl ester (1.93 g, 8.1 mmol, 1.0 eq.) in MeOH (20 mL) was added Palladium hydroxide and placed under H<sub>2</sub> for 4 h. The catalyst was filtered off through celite and rinsed with MeOH. The filtrate was concentrated (25 °C) to give **38** as reddish oil (840 mg, 100%).




39

[0183] To a suspension of NaH (8.99 g, 0.225 mol, 4.6 eq.) in DME (70 mL) at 0 °C was slowly added a solution of 1,4-dioxaspiro[4.5]decan-8-one (7.56 g, 0.048 mol, 1.0 eq.) in DME (24 mL). After stirring for 30 minutes, a solution of MeI (14 mL, 0.225 mol, 4.6 eq.) in DME (70 mL) was slowly introduced over 7 h and the resulting mixture was slowly warmed to room temperature and stirred overnight. The reaction was quenched by slow addition of water until no more bubbling observed. The reaction mixture was poured over iced water and extracted with 3xhexanes. The organic layers were combined, dried over MgSO<sub>4</sub>, filtered and concentrated. The crude mixture was purified by chromatography (100% hexanes to remove oil, then 5:1 Hexanes-EtOAc) to give 7,7,9,9-tetramethyl-1,4-dioxaspiro[4.5]decan-8-one (4.16 g, 40%).

[0184] To a solution of 7,7,9,9-tetramethyl-1,4-dioxaspiro[4.5]decan-8-one (4.15 g, 0.019 mol, 1.0 eq.) in THF (60 mL) was added 1 N HCl (30 mL) and the resulting mixture was stirred at room temperature overnight, concentrated to remove most of the THF, extracted with 3xEtOAc. The organic layers were combined, dried over MgSO<sub>4</sub>, filtered and concentrated to give 2,2,6,6-tetramethyl-cyclohexane-1,4-dione as a white solid (3.43 g, >100%).

[0185] To a solution of 2,2,6,6-tetramethyl-cyclohexane-1,4-dione (0.40 g, 2.4 mmol, 1.0 eq.) in THF (8 mL) was added molecular sieves (4Å, 80 mg), 2 M solution of MeNH<sub>2</sub> in THF (1.3 mL, 2.6 mmol, 1.1 eq.), and AcOH (0.17 mL, 3.0 mmol, 1.2 eq.). After 5 minutes of stirring, NaBH(OAc)<sub>3</sub> (0.71 g, 3.33 mmol, 1.4 eq.) was added and the resulting mixture was stirred at room temperature overnight. The reaction was quenched with the addition of saturated NaHCO<sub>3</sub>. The mixture was then concentrated and the aqueous layer was extracted with 3xEtOAc. The combined organic layers were washed once with saturated NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered and concentrated to give a crude pale yellow oil that was crystallized to give 39 as a white crystals (0.40 g, >100%).




40

**[0186]** To solution of methyltriphenylphosphonium bromide (17 g, 1.5 eq.) in THF (100 mL) at 0 °C was added dropwise n-butyllithium (2.5 M in hexanes, 18 mL, 1.4 eq.) and the resulting mixture was stirred for 1 h. A solution of 1,4-dioxa-spiro[4.5]decan-8-one (5.0 g, 32 mmol, 1.0 eq.) in THF (10 mL) was then introduced dropwise and the resulting mixture was warmed to room temperature and stirred overnight. The reaction was quenched by addition of sat. NaHCO<sub>3</sub> and the separated aqueous layer was extracted with 4x EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (5% to 10% EtOAc/hexanes) to give 8-methylene-1,4-dioxa-spiro[4.5]decane (3.92 g, 79%).

**[0187]** To a solution of 8-methylene-1,4-dioxa-spiro[4.5]decane (2.0 g, 13 mmol, 1.0 eq.) in THF (10 mL) at 0 °C was added dropwise 9-BBN (0.5 M in THF, 104 mL, 4.0 eq.) and the resulting mixture was stirred for 15 min and then warmed to room temperature and stirred overnight. Then NaBO<sub>4</sub> · 4H<sub>2</sub>O (32 g, 16 eq.) was introduced at 0 °C portionwise and the resulting mixture was warmed to room temperature and stirred overnight, diluted with hexanes (30 mL) and the separated aqueous phase was extracted with EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by silica gel chromatography (50% to 100% EtOAc-hexanes) to give (1,4-dioxa-spiro[4.5]dec-8-yl)-methanol (1.5 g, 67%).

**[0188]** To a solution of (1,4-dioxa-spiro[4.5]dec-8-yl)-methanol (1.0 g, 5.8 mmol, 1.0 eq.) and ethyldiisopropylamine (17 mL, 3.0 eq.) in methylene chloride (4 mL) at 0 °C was added dropwise MsCl (0.46 mL, 1.0 eq.) and the resulting mixture was warmed to room temperature and stirred for 2 h. The reaction was quenched by addition of sat. NaHCO<sub>3</sub> and the separated aqueous phase was extracted with 3x methylene chloride and 4x EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a crude methanesulfonic acid 1,4-dioxa-spiro[4.5]dec-8-ylmethyl ester.


**[0189]** A mixture of the crude methanesulfonic acid 1,4-dioxa-spiro[4.5]dec-8-ylmethyl ester (400 mg) in MeOH (2 mL) and aqueous MeNH<sub>2</sub> (40% w/w, 5 mL) was heated at reflux (60 °C oil bath) for overnight. The reaction was quenched by addition of sat. NaHCO<sub>3</sub> and the separated aqueous phase was extracted with 4x methylene chloride and 4x EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give crude **40** as brown oil.



41


[0190] To a solution of 4-oxo-piperidine-1-carboxylic acid benzyl ester (0.50 g, 2.14 mmol, 1.0 eq.) in THF (20 mL) was added dibromodifluoromethane (0.90 mL, 4.5 eq.) at  $-30^{\circ}\text{C}$  followed by HMPA (1.75 mL, 4.5 eq.). The cooling bath was removed and the reaction mixture was swirled periodically. After 30 min, zinc dust (0.63 g, 4.5 eq.) and HMPA (80  $\mu\text{L}$  0.4 eq.) was added and the mixture was heated at reflux for 18 h. Upon cooling to room temperature, the residue was washed with diethyl ether several times. The combined ether washings were washed successively with saturated aqueous copper (II) sulphate, brine, dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purification by chromatography (20% EtOAc-hexanes) to afford 4-difluoromethylene-piperidine-1-carboxylic acid benzyl ester (0.32 g, 56%) as a colorless oil.

[0191] A mixture of 4-difluoromethylene-piperidine-1-carboxylic acid benzyl ester (269 mg) and Pearlman's catalyst in methanol (2.5 mL) was stirred under hydrogen atmosphere (using hydrogen filled balloon) for 4 h at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated to give 41 (138 mg) as pale yellow oil.



42

[0192] Following the same procedure to prepare 41, 4-difluoromethylene-piperidine-1-carboxylic acid 2,2-dimethyl-propyl ester (368 mg) was prepared using 4-oxo-piperidine-1-carboxylic acid 2,2-dimethyl-propyl ester (500 mg). The 4-difluoromethylene-piperidine-1-carboxylic acid 2,2-dimethyl-propyl ester (368 mg) in methylene chloride (1.0 mL) at room temperature was treated with trifluoroacetic acid (TFA, 0.5 mL) for 1.5 h. After concentration of the reaction mixture, the crude 42 was used directly without further purification.



43

[0193] To a solution of 2-amino-cyclohexanol (3.50 g, 23.0 mmol, 1.0 eq.) in  $\text{CH}_2\text{Cl}_2$  (100 mL) was added ethylchloroformate (2.65 mL, 1.2 eq.) followed by an aqueous solution of


K<sub>2</sub>CO<sub>3</sub> (16.0 g in 200 mL of H<sub>2</sub>O). The mixture was stirred vigorously for 1h. The separated aqueous layer was extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over MgSO<sub>4</sub>, filtered and concentrated to give (2-hydroxy-cyclohexyl)-carbamic acid ethyl ester (4.36 g, >100 %).

[0194] To a solution of (2-hydroxy-cyclohexyl)-carbamic acid ethyl ester (2.06 g, 11.0 mmol, 1.0 eq.) in THF (80 mL) was added LiAlH<sub>4</sub> (1.09 g, 28.7 mmol, 2.6 eq.) and the resulting mixture was heated at 65 °C for 2 h. The reaction mixture was cooled to 0 °C, quenched with water, and the separated aqueous phase was extracted with 3xEtOAc. The combined organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated to give 2-methylamino-cyclohexanol (1.19 g, 84%).

[0195] To a solution of 2-methylamino-cyclohexanol (0.204 g, 1.58 mmol, 1.0 eq.) and di-*tert*-butyl dicarbonate (0.422 g, 1.2 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (7.0 mL) was added a solution of K<sub>2</sub>CO<sub>3</sub> in water (1.09 g in 14.0 mL of H<sub>2</sub>O) and the resulting mixture was stirred vigorously for 1 h. The separated aqueous layer was extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated to give (2-hydroxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (0.332 g, 92%).

[0196] To a solution of (2-hydroxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (0.237 g, 1.03 mmol, 1.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (7.0 mL) at 0 °C was added molecular sieves (4Å, 3 mL). The reaction was stirred for 5 minutes and then NMO (0.422 g, 3.5 eq.) and TPAP (0.025 g, 0.07 eq.) were introduced. The reaction mixture was stirred at 0 °C for 5 minutes, and then 40 minutes at room temperature. After diluted with hexanes, the reaction mixture was passed through a silica gel pad, using hexanes at the beginning to remove CH<sub>2</sub>Cl<sub>2</sub>, and then using a 1:1 mixture of hexanes-EtOAc to get the desired product. After concentration of the hexanes-EtOAc filtrate, methyl-(2-oxo-cyclohexyl)-carbamic acid *tert*-butyl ester was obtained as a white solid (0.235 g, 100%).


[0197] To a solution of methyl-(2-oxo-cyclohexyl)-carbamic acid *tert*-butyl ester (0.202 g, 0.89 mmol, 1.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL) was added TFA (1.0 mL) and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was then concentrated to give 43 (0.285 g, >100%).




44

[0198] To a solution of cyclopentylamine (5.8 mL, 59 mmol, 1.0 eq.) in  $\text{CH}_2\text{Cl}_2$  (250 mL) at room temperature was added ethylchloroformate (7.3 mL, 1.3 eq.) followed by an aqueous solution of  $\text{K}_2\text{CO}_3$  (37 g in 500 mL of  $\text{H}_2\text{O}$ ). The mixture was stirred vigorously for 1 h. The separated aqueous layer was extracted twice with  $\text{CH}_2\text{Cl}_2$ . The combined organic layers were dried over  $\text{MgSO}_4$ , filtered and concentrated to give cyclopentyl-carbamic acid ethyl ester (9.6g, 88%).


[0199] To a solution of the cyclopentyl-carbamic acid ethyl ester (6.00g, 32.4 mmol, 1.0 eq.) in THF (250 mL) was added  $\text{LiAlH}_4$  (3.08g, 2.5 eq.) and the resulting mixture was heated at 65 °C for 2 h. The reaction was then cooled to 0 °C and quenched by addition of water. The separated aqueous layer was extracted with 3xEtOAc. The combined organic phase was dried over  $\text{MgSO}_4$ , filtered and concentrated to give 44 (2.01 g, 62%).




45



46




47



48

[0200] Compounds 45-58 were prepared following the same procedures for the preparation of 44 from the corresponding primary amines.



49

[0201] To a solution of cyclopentanone (25.0 mL, 0.28 mol, 1.0 eq.) in toluene (100 mL), was added pyrrolidine (27.5 mL, 1.2 eq.). The reaction was equipped with a Dean-Stark and heated at reflux overnight. The reaction mixture was cooled to room temperature and concentrated to give the crude 1-cyclopent-1-enyl-pyrrolidine (45.8 g, >100%).

[0202] To a solution of  $\text{Pd}(\text{OAc})_2$  (0.06 g, 0.06 eq.),  $\text{PPh}_3$  (0.32 g, 0.24 eq.) and carbonic acid 2-ethoxycarbonyloxymethyl-allyl ester ethyl ester (1.23 g, 5.30 mmol, 1.0 eq., prepared following *Tetrahedron* 1998, 54(49), 14885-14904) in  $\text{CH}_3\text{CN}$  (30 ml) was added 1-cyclopent-1-enyl-pyrrolidine (1.01 g, 1.4 eq.) and the resulting mixture was heated at 45 °C for 35 minutes.

Then water (15 mL) was introduced and the reaction mixture was heated at 50 °C for 1 h, cooled to room temperature and diluted with EtOAc (30 mL). The separated aqueous phase was extracted twice with EtOAc. The combined organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated. The residue was purified by silica gel chromatography (10% to 15% EtOAc-hexanes) to give 3-methylene-bicyclo[3,2,1]octan-8-one (0.14 g, 70%) as a pale yellow liquid.

[0203] To a solution of 3-methylene bicyclo[3,2,1]octan-8-one (0.14 g, 1.04 mmol, 1.0 eq.) in benzene (10 mL) was added ethylene glycol (0.65 g, 16 eq.) and PTSA (0.01 g, 0.06 eq.). The reaction was equipped with a Dean-Stark and heated at reflux overnight. After cooling to room temperature, Et<sub>3</sub>N (0.15 mL) was introduced and the resulting mixture was passed through a cake of SiO<sub>2</sub> and MgSO<sub>4</sub>. The cake was washed with CH<sub>2</sub>Cl<sub>2</sub> and the combined filtrates were concentrated to give 3-methylene bicyclo[3,2,1]octan-8-one ethylene ketal (0.21 g, >100%).


[0204] To a solution of 3-methylenyl bicyclo[3,2,1]octan-8-one ethylene ketal (0.21 g, 1.15 mmol, 1.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at -78 °C was bubbled O<sub>3</sub> until the reaction stayed blue (about 3 min). The O<sub>3</sub> bubbling was stopped and the reaction mixture was stirred for 5 min at -78 °C. The reaction was quenched by addition of triphenylphosphine (0.43 g, 1.4 eq.) and stirring at -78 °C for 10 minutes. The reaction mixture was allowed to warm at room temperature, stirred for 40 minutes and concentrated. The residue was purified by silica gel chromatography (10% to 15% EtOAc-hexanes) to give bicyclo[3,2,1]octane-3,8-dione 8-ethylene ketal as a colorless oil (0.08 g, 40%).

[0205] To a solution of bicyclo[3,2,1]octane-3,8-dione 8-ethylene ketal (53.1 mg, 0.27 mmol, 1.0 eq.) in THF (1.0 mL) at 0 °C was added Et<sub>3</sub>N (0.11 mL, 2.9 eq.) followed by MeNH<sub>2</sub> (2.0 M in THF, 0.21 mL, 1.5 eq.). After stirring at room temperature for 5 minutes, TiCl<sub>4</sub> (0.30 mL, 10.0 eq.) was introduced dropwise and the resulting mixture was stirred at 0 °C for 45 minutes. A solution of NaBH<sub>4</sub> (53.1 mg, 5.1 eq.) in MeOH (2.0 mL) was then introduced and the resulting mixture was stirred at 0 °C for 1 h. The reaction was quenched with saturated NaHCO<sub>3</sub> and the separated aqueous layer was extracted with 3x EtOAc. The combined organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated to give the crude product, 3-methylamino-bicyclo[3,2,1]octan-8-one ethylene ketal (24.1 mg).

[0206] To a solution of 3-methylamino-bicyclo[3,2,1]octan-8-one ethylene ketal (94.5, 0.48 mmol, 1.0 eq.) in acetone (2.0 mL) was added 1N HCl (1.5 mL) and the reaction was stirred overnight at room temperature. The reaction mixture was neutralized with saturated NaHCO<sub>3</sub>



until pH was higher than 7, extracted with 3xEtOAc. The combined organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated to give **49** (40.0 mg, 54%).




**50**

[0207] To a solution of (3,3-dimethyl-1,5-dioxaspiro[5,5]undec-9-yl)-methyl-amine hydrochloride (1.0 g, 4 mmol, 1.0 eq.) in THF (12 mL) was added di-*tert*-butyl dicarbonate (1.1 mL, 1.2 eq.), triethylamine (2 mL) and DMAP (catalytical amount). The resulting mixture was heated at 90 °C for 6, cooled to room temperature, poured in saturated NaHCO<sub>3</sub>, and the separated aqueous layer was extracted with 3xEtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by silica gel chromatography (10% EtOAc/hexanes) to give (3,3-dimethyl-1,5-dioxaspiro[5,5]undec-9-yl)-methyl-carbamic acid *tert*-butyl ester (1.4 g, 91%) as a white solid.

[0208] To a solution of (3,3-dimethyl-1,5-dioxaspiro[5,5]undec-9-yl)-methyl-carbamic acid *tert*-butyl ester (1.27 g, 3.63 mmol, 1.0 eq.) in acetone (40 mL) and water (20 mL) was added PPTS (228 mg, 0.25 eq.) and the resulting reaction was heated to reflux overnight, cooled to room temperature, concentrated to 20 mL, poured in saturated NaHCO<sub>3</sub> and extracted with 3xEtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by silica gel chromatography (hexanes to 20% EtOAc/hexanes) to give methyl-(4-oxo-cyclohexyl)-carbamic acid *tert*-butyl ester (735 mg, 88%) as a white solid.

[0209] To a solution of methyl-(4-oxo-cyclohexyl)-carbamic acid *tert*-butyl ester (0.69 g, 3.04 mmol, 1.0 eq.) in THF (25 mL) at -30 °C was added CBr<sub>2</sub>F<sub>2</sub> (1.25 mL, 4.5 eq.) followed slow addition of by P(N(CH<sub>3</sub>)<sub>2</sub>)<sub>3</sub>. The resulting mixture was warmed to room temperature over 0.5 h and Zn was introduced. The resulting mixture was stirred at reflux for 16 h, cooled to room temperature and diluted with Et<sub>2</sub>O. The organic phase was decanted and the aqueous phase extracted with 2xEt<sub>2</sub>O. The combined organic phase was washed with saturated CuSO<sub>4</sub> solution until it stayed blue, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (20% EtOAc-Hexanes) to give (4-difluoromethylene-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (475 mg, 60%) as a white solid.

[0210] To a solution of (4-difluoromethylene-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (150 mg, 0.57 mmol, 1.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added TFA (1.5 mL). The reaction mixture was stirred for 4 h and then was concentrated to give **50** (85 mg). The crude compound was taken to the next step without further purification.




**51**

[0211] To a solution of cyclopropylamine (5.0 g, 87.5 mmol) and triethylamine (30 mL) in dichloromethane (100 mL) at 0 °C was added dropwise benzyl chloroformate (15.0 mL, 10.5 mmol) and the resulting mixture was stirred for 2 h. Additional benzyl chloroformate (1 mL) was added and the resulting reaction mixture was stirred overnight. The reaction was then quenched by addition of a saturated NaHCO<sub>3</sub> and the separated aqueous phase was extracted several times with dichloromethane. The combined dichloromethane extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (15% EtOAc to 5% MeOH/EtOAc) to give cyclopropyl-carbamic acid benzyl ester (11.8 g, 71%).

[0212] To a solution of cyclopropyl-carbamic acid benzyl ester (11.8 g) and methyl iodide (excess) in THF (80 mL) and DMF (20 mL) at 0 °C was added NaH (2.20 g, 91.6 mmol) and the resulting mixture was warmed to room temperature and stirred overnight. The reaction was then quenched at 0 °C by sat. NaHCO<sub>3</sub>. The separated aqueous phase was extracted several times with EtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (5% to 20% EtOAc/hexanes) to give cyclopropyl-methyl-carbamic acid benzyl ester (11.32 g, 91%).


[0213] A mixture of cyclopropyl-methyl-carbamic acid benzyl ester (10.7 g) and Pd(OH)<sub>2</sub> in MeOH (100 mL) was stirred at room temperature under H<sub>2</sub> balloon for 17 h, diluted with concentrated HCl (4.8 mL), filtered through celite and concentrated. The residue was azeotroped with toluene several times to give cyclopropyl-methyl-amine hydrochloride (**51**, 5.75 g). The crude material was used without further purification.



**52**

[0214] To a solution of (tetrahydro-furan-3-yl)-methanol (1.00 g, 9.79 mmol, 1.0 eq.), PPh<sub>3</sub> (3.85 g, 1.5 eq.) and imidazole (1.33 g, 2.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) at 0 °C was added I<sub>2</sub> (3.73 g, 1.5 eq.) and the resulting mixture was stirred at 0 °C for 30 min and then at room temperature for 30 min. The reaction mixture was diluted with sat. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution and the separated aqueous layer was extracted by 3x EtOAc and 4x CH<sub>2</sub>Cl<sub>2</sub>. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (15% EtOAc/hexanes) to give 3-iodomethyl-tetrahydro-furan as yellow oil (1.59 g, 76%).

[0215] A mixture of 3-iodomethyl-tetrahydro-furan (500 mg, 2.36 mmol, 1.0 eq.) and MeNH<sub>2</sub> (40% in H<sub>2</sub>O, 1.62 mL, 8.0 eq.) in MeOH (1 mL) was heated at 60 °C for 3 h. After cooling to room temperature, the reaction mixture was diluted with excess Et<sub>3</sub>N and concentrated. This process was repeated until no MeNH<sub>2</sub> was detected by <sup>1</sup>HNMR. The residual yellow oil (**52**) was used directly without further purification.




**53**

[0216] To a solution of 1-methoxymethyl-propylamine (2.50 g, 24.3 mmol, 1.0 eq.) in dioxane (15 mL) was added an aqueous solution of K<sub>2</sub>CO<sub>3</sub> (15 g in 15 mL of H<sub>2</sub>O) and the mixture was cooled to 0 °C. CBZ-Cl (4.16 mL, 1.2 eq.) was then introduced and the resulting mixture was warmed to room temperature and stirred for 3 h, extracted with EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (hexanes to 40% EtOAc/hexanes) to give (1-methoxymethyl-propyl)-carbamic acid benzyl ester (4.4 g, 76%) as a white solid.


[0217] To a solution of (1-methoxymethyl-propyl)-carbamic acid benzyl ester (4.4 g, 18.5 mmol, 1.0 eq.) and MeI (6.9 mL, 111 mmol, 6 eq.) in THF/DMF (4:1, 50 mL) at 0 °C was slowly added NaH (1.35 g, 55.5 mmol, 3 eq.). The resulting mixture was warmed to room temperature and stirred over night. The reaction was quenched carefully by slow addition of water until no bubbling (H<sub>2</sub>) was observed. The reaction mixture was poured over ice water and extracted with 3x EtOAc. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by silica gel chromatography (30% to 50% EtOAc-hexanes) to give (1-methoxymethyl-propyl)-methyl-carbamic acid benzyl ester (4.4 g, 94%).

[0218] To a solution of (1-methoxymethyl-propyl)-methyl-carbamic acid benzyl ester (4.4 g, 17.5 mmol, 1.0 eq.) in MeOH (30 mL) was added Palladium hydroxide and the resulting mixture was stirred at room temperature under H<sub>2</sub> for 1.5 h. The mixture was then filtered through celite and washed with MeOH. The filtrate was treated with concentrated HCl (1.6 mL, 1 eq.) and concentrated to give **53** (2.67 g, 100%). <sup>1</sup>H NMR confirmed the compound. The crude compound was used to the next step without further purification.




**54**

[0219] Compound **54** was prepared from (1-benzyl-2-hydroxy-ethyl)-carbamic acid benzyl ester following the same procedures of step 2 and 3 for the preparation of **53**.



**55**


[0220] (1-cyclohexylmethyl-2-hydroxy-ethyl)-methyl-carbamic acid benzyl ester was prepared from (1-cyclohexylmethyl-2-hydroxy-ethyl)-carbamic acid benzyl ester following the same procedure of step 2 for the preparation of **53**. (1-Cyclohexylmethyl-2-hydroxy-ethyl)-methyl-carbamic acid benzyl ester was then treated with TFA-CH<sub>2</sub>Cl<sub>2</sub> (1:1) at room temperature for 4 h. The mixture was then concentrated to give **55**.



**56**

[0221] To a solution of (R)-(-)-leucinol (2.0 g, 17 mmol, 1.0 eq.), Et<sub>3</sub>N (3.6 mL, 1.5 eq.) and DMAP (10 mg) in THF (2 mL) was added Boc<sub>2</sub>O (4.5 g, 1.2 eq.) at room temperature. After stirring for 5 h, the reaction was quenched by water and the separated aqueous phase was extracted with 4x ether. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (20% to 30% EtOAc/hexanes) to give (1-hydroxymethyl-3-methyl-butyl)-carbamic acid *tert*-butyl ester (1.9 g, 53%). <sup>1</sup>H NMR confirmed the compound.

[0222] Compound **56** was prepared from (1-hydroxymethyl-3-methyl-butyl)-carbamic acid *tert*-butyl ester following the same procedures for the preparation of **55**.




**57**

[0223] Methylolithium (1M in THF) (120 mL, 3.5 eq.) was added to a solution of 4-hydroxy-cyclohexanecarboxylic acid (cis/trans mixture) (5.00 g, 1 eq.) in THF (350 mL) at  $-78^{\circ}\text{C}$ . After stirring at  $-78^{\circ}\text{C}$  for 45 min, the cooling bath was removed and the resulting mixture was warmed to room temperature and stirred overnight. After total 24 h, the resulting reaction mixture was poured into ice/water (800 mL). This mixture was vigorously stirred. The separated aqueous phase was extracted with MeOH/EtOAc (~1/20). The combined organic layer was dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The crude product was purified by chromatography (50% to 100% EtOAc/hexanes) to give 1-(4-hydroxy-cyclohexyl)-ethanone (2.08 g, 42%).

[0224] A mixture of 1-(4-hydroxy-cyclohexyl)-ethanone (2.24g, 1 eq.), toluene (160 mL), neopentylglycol (1.96 g, 1.2 eq.) and pTsOH (150 mg, 0.05 eq.) in a flask equipped with Dean-Stark apparatus was heated to reflux overnight. The mixture was cooled down to room temperature and concentrated. The crude product was purified by silic gel column chromatography (25% to 50% EtOAc/hexanes) to give 4-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-cyclohexanol (2.23 g, 62%).

[0225] TPAP (161 mg, 0.05 eq.) was added to a solution of 4-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-cyclohexanol (2.22 g, 1 eq.) and NMO (2.28 g, 2 eq.) in MeCN (65 mL). The reaction mixture was stirred at room temperature overnight. Saturated aqueous solution of  $\text{Na}_2\text{S}_2\text{O}_3$  was added to the mixture and the resulting mixture was stirred vigorously for 15 minutes. The separated aqueous phase was extracted with  $\text{CH}_2\text{Cl}_2$ . The combined organic layer was dried over  $\text{Na}_2\text{SO}_4$ , filtered through Celite and concentrated. The crude product was purified by silica gel column chromatography (25% to 50% EtOAc/hexanes) to give 4-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-cyclohexanone (1.87 g, 85%)

[0226] Compound **57** was prepared from 4-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-cyclohexanone following the procedure for the preparation of **34** from 1,2-diphenyl-ethanone.




[0227] To a suspension of (3,3-dimethyl-1,5-dioxaspiro[5,5]undec-9-yl)-methyl-amine hydrochloride (6.9 g, 27.6 mmol, 1.0 eq.), Et<sub>3</sub>N (15 mL, 4.0 eq.) and DMAP (catalytic amount) in THF-MDF (1:1, 100 mL) was added di-*t*-butyl dicarbonate (7.6 mL, 1.2 eq.) and the resulting mixture was heated at 90 °C for 6 h. After cooling to room temperature, the reaction mixture was diluted with sat. NaHCO<sub>3</sub> and the separated aqueous layer was extracted with 2x EtOAc. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude product was purified by chromatography (10% to 20% EtOAc/hexanes) to give (3,3-dimethyl-1,5-dioxaspiro[5,5]undec-9-yl)-methyl-carbamic acid *tert*-butyl ester as a white solid (9.53 g, 99%).

[0228] A solution of (3,3-dimethyl-1,5-dioxaspiro[5,5]undec-9-yl)-methyl-carbamic acid *tert*-butyl ester (9.53 g, 27.2 mmol, 1.0 eq.) and PPTS (2.1 g, 0.3 eq.) in acetone-water (2:1, 500 mL) was heated at 80 °C for 18 h, cooled to room temperature and concentrated to remove acetone. The residual aqueous solution was diluted with NaHCO<sub>3</sub> and extracted with 2x EtOAc. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude product was purified by chromatography (20% to 50% EtOAc/hexanes) to give methyl-(4-oxo-cyclohexyl)-carbamic acid *tert*-butyl ester as a white solid (5.38 g, 87%).

[0229] To a solution of methyl-(4-oxo-cyclohexyl)-carbamic acid *tert*-butyl ester (134 mg, 0.59 mmol, 1.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) at room temperature was added (MeOCH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NSF<sub>3</sub> (217 µL, 2.0 eq.) followed by ethanol (10 µL, 0.3 eq.). After stirring for 1 h, the reaction was quenched carefully by addition of sat. NaHCO<sub>3</sub> and stirred until gas evolution ceased. The separated aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude mixture was purified by chromatography (5% to 10% EtOAc/hexanes) to give mixture of (4,4-difluoro-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester and (4-difluoro-cyclohex-3-enyl)-methyl-carbamic acid *tert*-butyl ester. To a solution of the mixture products in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at room temperature


was added trifluoroacetic acid (1.5 mL) at room temperature and the resulting mixture was stirred for 2.5 h and concentrated to give a mixture of **58** and **59** (2:1 ratio by  $^1\text{H}$ -NMR).



**[0230]** To a solution of 3-chloro-2-chloromethyl-1-propene (20.0 g, 160 mmol, 1.0 eq.) in THF (40 mL) at 0 °C was added NaOMe (100 mL of 25% solution in methanol, 2.8 eq.). After cooling bath was removed, the reaction mixture was stirred at room temperature for 20 h and at 35 °C for 20 h. The reaction was quenched with sat.  $\text{NH}_4\text{Cl}$  (10 mL) and the mixture was diluted with ether (200 mL) and filtered washing with ether. The filtrate was concentrated by distillation of ether, THF and EtOH at atmospheric pressure to give light yellow liquid residue. Fractional distillation of the residue gave 3-methoxy-2-methoxymethyl-1-propene (8.9 g, 43%). b.p. = 120-130 °C.

**[0231]** To a solution of the 3-methoxy-2-methoxymethyl-1-propene (3.5 g, 30 mmol, 1.0 eq.) in THF (10 mL) at 0 °C was added  $\text{BH}_3 \cdot \text{THF}$  (1M in THF, 18 mL, 0.6 eq.) and the resulting mixture was stirred for 40 min. The reaction was quenched with water followed by sodium perborate (10.6 g, 2.3 eq.), warmed to room temperature, stirred overnight, diluted with  $\text{CH}_2\text{Cl}_2$  and filtered through celite. The filtrate was diluted with brine and the separated aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$ . The combined extracts were dried over  $\text{Na}_2\text{SO}_4$  and filtered. The filtrate was distilled at atmospheric pressure to give light yellow liquid residue. Fractional distillation of the residue at 40 milliTorrs gave 3-methoxy-2-methoxymethylpropan-1-ol (1.93 g, 48%). b.p. = 90-110 °C.

**[0232]** To a solution of alcohol 3-methoxy-2-methoxymethylpropan-1-ol (0.90 g, 6.7 mmol, 1.0 eq.) in  $\text{CH}_2\text{Cl}_2$  (10 mL) at 0 °C was added  $\text{Et}_3\text{N}$  (1.9 mL, 2.0 eq.) followed by  $\text{MsCl}$  (0.63 mL, 1.2 eq.). After stirring for 40 min, the reaction was quenched with methylamine (40% in water). After concentration of the reaction mixture at room temperature, the residue was diluted with methanol (2 mL) and methylamine (3 mL, 40% in water), heated at 50 °C for 18 h cooled to room temperature, saturated with  $\text{Na}_2\text{CO}_3$  and extracted with ether. The combined extracts were dried over  $\text{Na}_2\text{SO}_4$  and filtered. The filtrate was distilled at atmospheric pressure to give crude product **60** (0.78 g, 80%) as a light yellow liquid.




**61**

[0233] To a solution of trans-4-amino-cyclohexanol hydrochloride (5.0 g, 32.9 mmol, 1.0 eq.) in water (80 mL) and THF (60 mL) at room temperature was added  $\text{NaHCO}_3$  (6.4 g, 2.3 eq.) and  $(\text{Boc})_2\text{O}$  (14.8 mL, 2.0 eq.). After stirring for 48 h, most of THF from reaction mixture was removed by concentration and the aqueous residue was extracted with EtOAc. The combined organic extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The crude product was crystallized from EtOAc-hexanes (9:1) to give (4-trans-hydroxy-cyclohexyl)-carbamic acid *tert*-butyl ester (5.2 g, 75%).

[0234] To a solution of (4-trans-hydroxy-cyclohexyl)-carbamic acid *tert*-butyl ester (3.0 g, 13.9 mmol, 1.0 eq.) and methyl iodide (4.3 mL, 5.0 eq.) in N-methyl-2-pyrrolidinone (NMP) (50 mL) at 0 °C was added 60% NaH in mineral oil (1.67 g, 3.0 eq.) in a controlled portion wise manner and the resulting mixture was stirred for 3 h at room temperature. The reaction mixture was quenched with methanol (3.0 mL), stirred for 30 min, diluted with sat.  $\text{NH}_4\text{Cl}$  and the mixture was extracted three times with EtOAc. The combined organic extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The crude mixture was purified by silica gel chromatography (20% EtOAc/hexanes) to give (4-trans-methoxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (3.25 g, 96%).


[0235] To a solution of trans-(4-methoxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (445 mg, 1.83 mmol, 1.0 eq.) in  $\text{CH}_2\text{Cl}_2$  (2 mL) at room temperature was added trifluoroacetic acid (2 mL). After stirring for 2 h, the reaction mixture was concentrated to give **61** (685 mg, 145%, contains residual TFA).  $^1\text{H}$  NMR confirmed the structure and the product was used without further purification.

[0236] Alternatively, compound **61** may be prepared according to the following scheme:






[0237] Thus, oxidation of 4-methoxy cyclohexanol under suitable conditions (*e.g.*, TPAP, NMO) in a suitable solvent (*e.g.*, methylene chloride) gives the corresponding ketone. Reductive amination of 4-methoxy cyclohexanone under suitable conditions (*e.g.*, dimethylamine, NaBH(OAc)<sub>3</sub>, AcOH in THF) gives access to the corresponding amine **61** with good stereoselectivity (*i.e.*, *trans*).



**62**

[0238] To a suspension of methyl-(4-oxo-cyclohexyl)-carbamic acid *tert*-butyl ester (an intermediate for the preparation of **58** and **59**, 580 mg, 2.56 mmol, 1.0 eq.) in THF (8 mL) at -78 °C was added LS-selectride (1 M solution in THF, 5.7 mL, 2.2 eq.). After stirring for 2.5 h, the reaction mixture was warmed to 0 °C and stirred for 30 min. The reaction was quenched with sat. NH<sub>4</sub>Cl and the separated aqueous layer was extracted with EtOAc-hexanes (1:1). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude mixture was purified by silica gel chromatography (33% to 50% EtOAc/hexanes) to give (4-cis-hydroxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (391 mg, 67%).


[0239] Compound **62** was prepared from (4-cis-hydroxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester following the same procedure for the preparation of **61** from (4-trans-hydroxy-cyclohexyl)-carbamic acid *tert*-butyl ester.



**63**

[0240] To a solution of (4-cis-hydroxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (1.95 g, 8.52 mmol, 1.0 eq.) in DMF (20 mL) at 0 °C was added NaH (559 mg, 2.5 eq.). After stirring for 10 min, methyl iodide (3.9 mL, 7.6 eq.) was introduced and the cooling bath was removed. After stirring for 5 h at room temperature, the reaction was quenched with methanol (1.5 mL), stirred for 15 min and diluted with sat. NH<sub>4</sub>Cl. The mixture was extracted with EtOAc-hexanes (1:1). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude mixture was purified by silica gel chromatography (10% to 25% EtOAc/hexanes) to give (4-cis-methoxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (1.73 g, 84%).

[0241] To a solution of (4-cis-methoxy-cyclohexyl)-methyl-carbamic acid *tert*-butyl ester (1.73 g, 7.12 mmol, 1.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) at room temperature was added trifluoroacetic acid (4 mL). After stirring for 3.5 h, the reaction mixture was concentrated to give a crude product. This product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and washed with sat. Na<sub>2</sub>CO<sub>3</sub> (40 mL). The aqueous layer was back extracted with 5xCH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give free amine **63** (1.12 g, 109%, contains residual CH<sub>2</sub>Cl<sub>2</sub>).




**64**

[0242] A mixture of **18** (0.01-0.1 M, 1.0 eq.), diisopropylethylamine (5.0 eq.) and any one of amine from **21-63** or other commercially available primary or secondary alkylamine (3-10 eq.) in dichloromethane was stirred at room temperature or at 40°C for several hours to five days until reaction was completed. The reaction mixture was concentrated and the intermediate product, either with or without purification by chromatography (EtOAc/hexanes), was dissolved in 1:1 mixture of dichloromethane and trifluoroacetic acid (0.05 M) and stirred at room temperature with or without anisole (5-10 eq.) for 3-4 h until reaction was completed. The reaction was then carefully quenched with sat. NaHCO<sub>3</sub>, extracted with EtOAc until there was no product detected. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product **64** was purified by reverse phase HPLC (MeOH-water).

[0243] The following procedure has been used for aromatic amines (R<sub>F</sub> and/or R<sub>G</sub>=Ar). To a solution of N-ethylaniline (47 μL, 6 eq.) in THF (1 mL) at -78 °C was added nBuLi (148 μL, 2.5 M in hexanes, 6 eq.) followed by HMPA (200 μL) and stirred for 10 min. A solution of **18** (44 mg, 0.062 mmol) in THF (0.7 mL) was introduced by rinsing with THF (0.3 mL). After 10 min stirring, the reaction mixture was quenched with sat. NaHCO<sub>3</sub> (15 mL), extracted with 3xEtOAc. The combine extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (EtOAc) to give an intermediate. This intermediate and anisole (100 μL) was dissolved in 1:1 mixture of dichloromethane and trifluoroacetic acid (2 mL) and

stirred at room temperature 3 h. The reaction was then carefully quenched with sat. NaHCO<sub>3</sub>, extracted with 4xEtOAc. The combine extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product **64** was purified by reverse phase HPLC (MeOH-water).










**65**









[0244] Diisopropylethylamine (1.6 eq.) was added to a solution of **20** (0.03-0.05 M, 1.0 eq.) and TOTU (1.5 eq.) in DMF at room temperature and stirred for 15 min. To the resulting mixture was added any one amine from **21-63** or other commercially available primary or secondary amine (1.5 eq.). The reaction mixture was stirred for several hours to overnight until reaction completed. The reaction mixture was concentrated and the intermediate product, either with or without purification by chromatography (EtOAc/hexanes), was dissolved in 1:1 mixture of dichloromethane and trifluoroacetic acid (0.01-0.05M) and stirred at room temperature with or without anisole (5-10 eq.) for 3-4 h until reaction was completed. The reaction was then carefully quenched with sat. NaHCO<sub>3</sub>, extracted with EtOAc until there was no product detected. The combine extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product **65** was purified by reverse phase HPLC (MeOH-water).

[0245] Compounds in the following table were prepared either following the preparation of **13** or **64** or **65**.








Compound # (ER # or IC#)	Structure of <b>64</b> or <b>65</b>	MS (ES) Or/And <sup>1</sup> HNMR

806094		$^1\text{H NMR}$
806095		$^1\text{H NMR}$
806123		$361.4 (\text{M}+\text{H})^+$
806136		$404.3 (\text{M}+\text{H})^+$
806181		$^1\text{H NMR}$
806221		$413.3 (\text{M}+\text{H})^+$
806220		$465.3 (\text{M}+\text{H})^+$

806224		409.3 (M+H) <sup>+</sup>
806228		412.3 (M+H) <sup>+</sup>
806276		471.3 (M+H) <sup>+</sup>
806275		487.3 (M+H) <sup>+</sup>
806274		397.3 (M+H) <sup>+</sup>
806273		411.3 (M+H) <sup>+</sup>
806317		398.2 (M+H) <sup>+</sup>

806320		417.2 (M+H) <sup>+</sup>
806329		424.3 (M+H) <sup>+</sup>
806333		497.3 (M+H) <sup>+</sup> 520.2 (M+Na) <sup>+</sup>
806336		411.3 (M+H) <sup>+</sup>
806358		397.2 (M+H) <sup>+</sup>
806359		383.3 (M+H) <sup>+</sup>
806363		462.2 (M+H) <sup>+</sup>
806362		440.3 (M+H) <sup>+</sup>







806361		479.2 (M+H) <sup>+</sup>
806368		369.2 (M+H) <sup>+</sup>
806372		495.2 (M+H) <sup>+</sup>
806373		499.2 (M+H) <sup>+</sup>
806374		483.2 (M+H) <sup>+</sup>
806375		384.3 (M+H) <sup>+</sup>
806383		363.3 (M+H) <sup>+</sup>
806393		512.2 (M+H) <sup>+</sup>









<b>806402</b>		411.2 (M+H) <sup>+</sup> 433.2 (M+Na) <sup>+</sup>
<b>806417</b>		397.1 (M+H) <sup>+</sup>
<b>806419</b>		469.2 (M+H) <sup>+</sup>
<b>806421</b>		511.2 (M+H) <sup>+</sup>
<b>806435</b>		411.3 (M+H) <sup>+</sup>
<b>806437</b>		411.3 (M+H) <sup>+</sup>
<b>806569</b>		452.3 (M+H) <sup>+</sup>





















806790		509.3 (M-H) <sup>-</sup>
806796		<sup>1</sup> H NMR
806820		496.3 (M+H) <sup>+</sup>
806839		467.2 (M+Na) <sup>+</sup>
806840		467.2 (M+Na) <sup>+</sup>
806841		445.3 (M+H) <sup>+</sup>
806842		397.3 (M+H) <sup>+</sup>









806843		483.3 (M+H) <sup>+</sup> 505.3 (M+Na) <sup>+</sup>
806844		363.3 (M+H) <sup>+</sup> 385.3 (M+Na) <sup>+</sup>
806860		496.3 (M+H) <sup>+</sup>
806874		<sup>1</sup> H NMR
806875		<sup>1</sup> H NMR
806878		<sup>1</sup> H NMR

806899		$^1\text{H NMR}$
806900		$^1\text{H NMR}$
806901		$497.1 (\text{M}+\text{H})^+$
806902		$377.3 (\text{M}+\text{H})^+$
806903		$431.1 (\text{M}+\text{H})^+$
806904		$431.2 (\text{M}+\text{H})^+$
806905		$431.2 (\text{M}+\text{H})^+$
806987		$441.3 (\text{M}+\text{H})^+$ $463.2 (\text{M}+\text{Na})^+$

<b>807014</b>		$343.3 (M+Na)^+$
<b>807139</b>		$^1H$ NMR
<b>807140</b>		$427.3 (M+H)^+$
<b>807183</b>		$463.3 (M+Na)^+$ $441.3 (M+H)^+$
<b>807240</b>		$427.2 (M+H)^+$









<b>807377</b>		$^1H$ NMR
<b>807392</b>		$^1H$ NMR









807400		$^1\text{H NMR}$
807401	 Trans racemic	$^1\text{H NMR}$
807399	 Cis racemic	$^1\text{H NMR}$
807447		$^1\text{H NMR}$
807448		$^1\text{H NMR}$
807449		$^1\text{H NMR}$
807450		$481.1 (\text{M}+\text{H})^+$
807451		$481.1 (\text{M}+\text{H})^+$
807452		$465.1 (\text{M}+\text{H})^+$









807453		$^1\text{H NMR}$
807454		$^1\text{H NMR}$
807457		$^1\text{H NMR}$
807458		$^1\text{H NMR}$
807459		$^1\text{H NMR}$
807460		$481.1 (\text{M}+\text{H})^+$
807460		$^1\text{H NMR}$
807463		$^1\text{H NMR}$









807464		<sup>1</sup> H NMR
807465		<sup>1</sup> H NMR
807466		<sup>1</sup> H NMR
807467		<sup>1</sup> H NMR
807469		<sup>1</sup> H NMR
807497		<sup>1</sup> H NMR
807498		<sup>1</sup> H NMR
807505		<sup>1</sup> H NMR










807506		<sup>1</sup> H NMR
807528		<sup>1</sup> H NMR
807531		<sup>1</sup> H NMR
807532		<sup>1</sup> H NMR
807543		<sup>1</sup> H NMR
807544		<sup>1</sup> H NMR
807548		<sup>1</sup> H NMR
807549		<sup>1</sup> H NMR

807550		$^1\text{H NMR}$
807562		$^1\text{H NMR}$
807571		$^1\text{H NMR}$
807573		$387.3 (\text{M}+\text{H})^+$
807586		$^1\text{H NMR}$
807636		$^1\text{H NMR}$
807649		$^1\text{H NMR}$
807660		$^1\text{H NMR}$








807662		<sup>1</sup> H NMR
807663		<sup>1</sup> H NMR
807703		<sup>1</sup> H NMR
807704		<sup>1</sup> H NMR
807748		<sup>1</sup> H NMR
807749		<sup>1</sup> H NMR
807751		<sup>1</sup> H NMR
807754		<sup>1</sup> H NMR

<b>807758</b>		<sup>1</sup> H NMR
<b>807762</b>		<sup>1</sup> H NMR
<b>807779</b>		<sup>1</sup> H NMR
<b>807794</b>		<sup>1</sup> H NMR
<b>807836</b>		<sup>1</sup> H NMR
<b>807862</b>		<sup>1</sup> H NMR
<b>807876</b>		<sup>1</sup> H NMR
<b>807892</b>		<sup>1</sup> H NMR









<b>807920</b>		<sup>1</sup> H NMR
<b>807930</b>		<sup>1</sup> H NMR
<b>807931</b>		<sup>1</sup> H NMR
<b>807952</b>		<sup>1</sup> H NMR
<b>807956</b>		<sup>1</sup> H NMR
<b>807962</b>		<sup>1</sup> H NMR
<b>807977</b>		<sup>1</sup> H NMR









807978		<sup>1</sup> H NMR
807980		<sup>1</sup> H NMR
808028		<sup>1</sup> H NMR
808039		<sup>1</sup> H NMR
808069		<sup>1</sup> H NMR
808078		<sup>1</sup> H NMR
808079		<sup>1</sup> H NMR
808084		<sup>1</sup> H NMR




808254		<sup>1</sup> H NMR
808255		<sup>1</sup> H NMR
808283		<sup>1</sup> H NMR
808290		<sup>1</sup> H NMR
808312		<sup>1</sup> H NMR
808313		<sup>1</sup> H NMR
808346		<sup>1</sup> H NMR




808347		$^1\text{H}$ NMR
808355		$^1\text{H}$ NMR
808356		$^1\text{H}$ NMR
808364		$^1\text{H}$ NMR
808365		$^1\text{H}$ NMR
808371		$^1\text{H}$ NMR
808387		$^1\text{H}$ NMR
808548		$^1\text{H}$ NMR

808661		<sup>1</sup> H NMR
808663		<sup>1</sup> H NMR
808665		<sup>1</sup> H NMR
808675		<sup>1</sup> H NMR
808702		<sup>1</sup> H NMR
808833		<sup>1</sup> H NMR
808836		<sup>1</sup> H NMR
808984		<sup>1</sup> H NMR




**ER-806286**

[0246] Diethyl azodicarboxylate (9.1  $\mu$ L, 2.0 eq.) was added to a solution of **17** (20 mg, 0.03 mmol, 1.0 eq.), triphenylphosphine (15 mg, 2.0 eq.) and phthalimide (8.5 mg, 2.0 eq.) in toluene (2 mL) at room temperature and the resulting mixture was stirred for 19 h. The reaction mixture was concentrated and the intermediate was purified by chromatography (30% EtOAc-hexanes) to give 19.3 mg (81%). This intermediate was dissolved in 1:1 mixture of dichloromethane and trifluoroacetic acid (2 mL) and stirred at room temperature for 2 h until reaction was completed. The reaction was then carefully quenched with sat.  $\text{NaHCO}_3$  (15 mL), extracted with 7x10 mL of EtOAc. The combine extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated and the product was purified by reverse phase HPLC (MeOH-water) to give **ER-806286** (2.4 mg, 24%). MS (ES) 423.2 ( $\text{M}+\text{H}$ )<sup>+</sup>.




**ER-806287**

[0247] Compound **ER-806287** was prepared from 4-trifluoromethylphenol following the same procedure for the preparation of **ER-806286**. MS (ES) 438.2 ( $\text{M}+\text{H}$ )<sup>+</sup>.



**ER-806311**


[0248] A mixture of **18** (12.5 mg, 0.018 mmol), diisopropylethylamine (0.2 mL, 65 eq.) and thiophenol (10  $\mu$ L, 5.5 eq.) in DMF (0.5 mL) at room temperature was stirred for two days. The reaction mixture was concentrated and purified by chromatography (30% EtOAc-hexanes) to give an intermediate 12.7 mg (92%). This intermediate and anisole (100  $\mu$ L) were dissolved in 1:1 mixture of dichloromethane and trifluoroacetic acid (2 mL) and stirred at room temperature for 40 min. The reaction was then carefully quenched with sat.  $\text{NaHCO}_3$  (15 mL), extracted with 7x EtOAc. The combine extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated and the product was purified by chromatography (5% MeOH-EtOAc) to give **ER-806311** (4.5 mg, 65%). MS (ES) 386.2 ( $\text{M}+\text{H}$ )<sup>+</sup>.



**ER-806355**


[0249] Methylsulfonyl chloride (9  $\mu$ L, 2 eq.) was added to a solution of **17** (40.5 mg, 0.058 mmol) and diisopropylethylamine (100  $\mu$ L, 10 eq.) in dichloromethane (1 mL) at 0 °C and stirred for 30 min. 4-hydroxypiperidine (30 mg, 5.0 eq.) and DMF (0.5 mL) were introduced and the reaction mixture was warmed to room temperature and stirred for 2.5 days. The reaction was quenched with sat.  $\text{NaHCO}_3$  (10 mL) and the separated aqueous phase was extracted with 4x EtOAc. The combine organic extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated and the product was purified by reverse HPLC (MeOH-water) to give an intermediate (25 mg, 65%). This intermediate was dissolved in dichloromethane (0.5 mL) and treated with TPAP (5 mg) and NMO (20 mg) at room temperature for 10 min. The reaction was quenched by addition of water and  $\text{Na}_2\text{S}_2\text{O}_3$  extracted with 4x EtOAc. . The combine organic extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated and the product was purified by chromatography (15% EtOAc-hexanes) to give an intermediate (13.7 mg). This intermediate and anisole (100  $\mu$ L) were dissolved in dichloromethane (1 mL) and treated with trifluoroacetic acid (1 mL) at room temperature for 4 h. The reaction was then carefully quenched with sat.  $\text{NaHCO}_3$  (15 mL), extracted with 4x EtOAc. The combine extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated and the product was purified by reverse phase HPLC ( MeOH-water) to give **ER-806355** (3.4

mg, 16% for three steps).  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  2.35 (t,  $J=6$  Hz, 4H), 2.49 (s, 3H), 2.70 (t,  $J=6$  Hz, 4H), 3.67 (s, 2H), 5.74 (s, 2H), 6.73 (s, 1H), 7.16 (dd,  $J=8.2$  and 1.2 Hz, 1H), 7.28 (d,  $J=1.2$  Hz, 1H), 7.53 (d,  $J=8.2$ , 1H), 7.55 (s, 1H).




**ER-806401**

[0250] Hydrogen peroxide (4 mL, 30% in water, 3.6 eq.) was added to a solution of thiomorpholine (1.0 g, 9.7 mmol) in acetic acid (12 mL) at room temperature. The resulting mixture was stirred at 100 °C overnight, cooled to room temperature and concentrated. Thiomorpholine sulfoxide from the residue was crystallized from ethanol as a deep colored solid. Following the general procedure for the preparation of **64**, compound **ER-806401** was prepared from **18** and Thiomorpholine sulfoxide. MS (ES) 417.2 ( $\text{M}+\text{Na}^+$ ).



**ER-806404**

[0251] A mixture of **18** (5 mg) and benzyl alcohol (100  $\mu\text{L}$ ) was treated with tBuOK (1 mL, 1.66 M in THF) at room temperature overnight. The reaction mixture was quenched with sat.  $\text{NaHCO}_3$  and extracted with 3xEtOAc. The combine extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated and the crude intermediate and anisole (50  $\mu\text{L}$ ) were dissolved in dichloromethane (0.5 mL) and treated with trifluoroacetic acid (0.5 mL) at room temperature for 3 h. The reaction was then carefully quenched with sat.  $\text{NaHCO}_3$ , extracted with 4xEtOAc. The combine extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated and the product was purified by thin layer chromatograph (10% MeOH/EtOAc) to give **ER-806404** (1.0 mg, 37%). MS (ES) 384.2 ( $\text{M}+\text{H}^+$ ).




**ER-806644**

[0252] To a solution of 5-iodoindole (5.0 g, 20.6 mmol), phenylacetylene (3.4 mL, 1.5 eq.) and diethylamine (10 mL) in DMF (2 mL) was added  $\text{Pd}(\text{Ph}_3\text{P})_4$  (120 mg, 0.005 eq.) and  $\text{CuI}$  (39 mg, 0.01 eq.) under nitrogen atmosphere at cooling water both temperature and the resulting mixture was stirred for 3h at room temperature. The reaction was diluted with sat.  $\text{NaHCO}_3$  (50 mL), extracted with 4x30 mL of EtOAc. The combined extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated and the product was purified by chromatograph (15 to 20% EtOAc/hexanes) to give 5-phenylethynyl-1H-indole (4.41 g, 98%).

[0253] Compound 5-phenylethynyl-lindole-1-carboxylic acid *tert*-butyl ester was prepared from 5-phenylethynyl-1H-indole following the procedure for the preparation of 7 (indole-1,5-dicarboxylic acid 1-*tert*-butyl ester 5-methyl ester as an example) from methyl indole-5-carboxylate.

[0254] Compound 5-phenylethynyl-2-tributylstannanyl-indole-1-carboxylic acid *tert*-butyl ester was prepared from 5-phenylethynyl-lindole-1-carboxylic acid *tert*-butyl ester following the procedure for the preparation of 10 from 9.


[0255] Compound **ER-806644** was prepared from 5-phenylethynyl-2-tributylstannanyl-indole-1-carboxylic acid *tert*-butyl ester and 4 ( $\text{R}_1=\text{Me}$ ) following the procedure for the preparation of 13. MS (ES) 364.2 ( $\text{M}+\text{H}$ )<sup>+</sup>.



**ER-806645**


[0256] A solution of **ER-806644** (6.5 mg) and Lindlar catalyst (50 mg) in THF (2 mL) was stirred at room temperature under hydrogen gas for 1 h. The resulting mixture was filtered

through celite and the filtrate was concentrated. The residual solid was washed several times with EtOAc to give **ER-806645** as a light yellow solid (2.0 mg, 31%). MS (ES) 366.3 (M+H)<sup>+</sup>.




**ER-806646**

[0257] A solution of **ER-806644** (5 mg) and Pd(OH)<sub>2</sub> (10 mg) in THF (2 mL) was stirred at room temperature under hydrogen gas for overnight. The resulting mixture was filtered through celite and the filtrate was concentrated and the product was purified by reverse phase HPLC (MeOH-water) to give **ER-806646** (1.3 mg, 26%). MS (ES) 368.3 (M+H)<sup>+</sup>.



**ER-806095**


[0258] A solution of **16** (20 mg) in 1:1 THF-MeOH (3 mL) at room temperature was treated with a solution of 1 N HCl (0.5 mL) for 30 min. The reaction mixture was diluted with sat. NaHCO<sub>3</sub> and extracted with EtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by reverse phase HPLC (MeOH-water) to give **ER-806095** (2.6 mg, 18%). <sup>1</sup>H NMR.



**ER-806420**

[0259] A solution of **ER-806393** (1.3 mg) in MeOH (0.5 mL) was treated at room temperature with a solution of 1 N LiOH (0.1 mL) for overnight. The reaction mixture was then neutralized with a solution of 1 N HCl (0.1 mL) to pH=5 and concentrated. The residue was


taken up in 1:1 MeOH-EtOAc and filtered. The filtrate was concentrated and purified by reverse phase HPLC (MeOH-water) to give **ER-806420** (0.5 mg, 40%). MS (ES) 496.3 (M-H)<sup>-</sup>.



**ER-806432**

[0260] A mixture of **18** (15.5 mg, 0.02 mmol) and methylamine (0.11 mL, 2.0 M in THF, 1.0 eq.) in dichloromethane (0.5 mL) was stirred at room temperature overnight, diluted with sat.NaHCO<sub>3</sub> and extracted with 3xEtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was dissolved in DMF (0.5 mL) as a solution A.

[0261] Diisopropylethylamine (5.3  $\mu$ L, 1.4 eq.) was added to a solution of benzoic acid (3.4 mg, 1.3 eq.) and TOTU (10 mg, 1.4 eq.) in DMF (0.3 mL) at room temperature and stirred for 15 min. Solution A was then introduced by rinsing with 3x0.5 mL of DMF and the resulting mixture was stirred overnight, concentrated, diluted with sat.NaHCO<sub>3</sub> and extracted with 3xEtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue and anisole (50  $\mu$ L) was dissolved in dichloromethane (0.5 mL) and treated with trifluoroacetic acid (0.5 mL) at room temperature for 3 h. The reaction mixture was carefully quenched with sat.NaHCO<sub>3</sub> and EtOAc and the separated aqueous phase was extracted with 3xEtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by reverse phase HPLC (MeOH-water) to give **ER-806432** (1.4 mg, 16% for three steps). MS (ES) 411.2 (M+H)<sup>+</sup>.



**ER-807313**

[0262] 5-nitro-indole-1-carboxylic acid *tert*-butyl ester was prepared from 5-nitroindole following the same procedure for the preparation of **7** from methyl indole-5-carboxylate.



[0263] A solution of 5-nitro-indole-1-carboxylic acid *tert*-butyl ester (0.50 g) and catalytic amount of Pd(OH)<sub>2</sub> in a mixture of MeOH-EtOAc was stirred at room temperature under hydrogen for 1 h. The reaction mixture was filtered through celite and the filtrate was concentrated to provide 5-amino-2,3-dihydro-indole-1- carboxylic acid *tert*-butyl ester (0.44 g, 98%).


[0264] Benzoyl chloride (305  $\mu$ L, 1.5 eq.) was added to a solution of 5-amino-2,3-dihydro-indole-1- carboxylic acid *tert*-butyl ester (407 mg, 1.74 mmol) and triethylamine (1.2 mL, 5.0 eq.) in dichloromethane (5 mL) at 0 °C and the resulting mixture was stirred for 15 min. The reaction was then quenched by addition of sat. NaHCO<sub>3</sub> and the mixture was extracted with 3xEtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (20 to 100% EtOAc-hexanes) to give 5-benzoylamino-2,3-dihydro-indole-1- carboxylic acid *tert*-butyl ester (588 mg, 100%).

[0265] Sodium hydride (60 mg, 1.5 eq.) was added to a mixture of 5-benzoylamino-2,3-dihydro-indole-1- carboxylic acid *tert*-butyl ester (570 mg, 1.68 mmol) and methyl iodide (0.42 mL, 4.0 eq.) in DMF (10 mL) at 0 °C and the resulting mixture was stirred for 20 min. After concentration, the residue from reaction mixture was diluted with sat. NaHCO<sub>3</sub> and extracted with 3xEtOAc. The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and the product was purified by chromatography (30% EtOAc-hexanes) to give 5-(benzoyl-methyl-amino)-2,3-dihydro-indole-1- carboxylic acid *tert*-butyl ester (547 mg, 93%).

[0266] A mixture of 5-(benzoyl-methyl-amino)-2,3-dihydro-indole-1- carboxylic acid *tert*-butyl ester (500 mg) and MnO<sub>2</sub> (5 g) in toluene (20 mL) was heated at 80 °C for 1h. Additional MnO<sub>2</sub> (5 g) was introduced and the resulting mixture was stirred at 80 °C for 1h. After cooling to room temperature, the mixture was filtered through celite and the filtrate was concentrated. The product was purified by chromatography (30% EtOAc-hexanes) to give 5-(benzoyl-methyl-amino)-indole-1-carboxylic acid *tert*-butyl ester (372 mg, 75%).


[0267] 5-(benzoyl-methyl-amino)-2-tributylstrannanyl-indole-1-carboxylic acid *tert*-butyl ester was prepared from 5-(benzoyl-methyl-amino)-indole-1-carboxylic acid *tert*-butyl ester following the procedure for the preparation of **10** from **9**.

[0268] Compound **ER-807313** was prepared from 5-(benzoyl-methyl-amino)-2-tributylstrannanyl-indole-1-carboxylic acid *tert*-butyl ester and **4** (R<sub>1</sub>=Me) following the procedure for the preparation of **13**. MS (ES) 397.2 (M+H)<sup>+</sup> and 419.1 (M+Na)<sup>+</sup>.




**ER-807015**

[0269] Compound **ER-807015** was prepared as a by-product during preparation of **65** from sterically hindered amines and yielded a satisfactory  $^1\text{H}$  NMR spectrum.




**ER-807586**

[0270] A mixture of **18** (51 mg, 1.0 eq.), (3,3-dimethyl-1,5-dioxaspiro[5,5]undec-9-yl)-methyl-amine hydrochloride (71 mg, 4.0 eq.), ethyldiisopropylamine (0.25 mL, 20 eq.) and DMF (0.3 mL) in  $\text{CH}_2\text{Cl}_2$  (2.5 mL) was stirred at room temperature for 23 h. After concentration, the residue was dissolved in 1 N HCl (0.6 mL) and acetone (0.6 mL) and heated at reflux for 16 h. After cooling to room temperature, the reaction was then carefully quenched with sat.  $\text{NaHCO}_3$ , extracted with EtOAc until there was no product detected. The combine extracts were dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated and the product was purified by reverse phase HPLC (MeOH-water) to give **ER-807586** (6.4 mg, 22%).  $^1\text{H}$ NMR and MS (ES) 403.5 ( $\text{M} + \text{H}$ ) $^+$ .




**ER-807759**

[0271] **ER-807759** was prepared following the same procedure for **13** (**ER-805639** as an example) in Stille coupling reaction and for **ER-807586** in ketal hydrolysis reaction.  $^1\text{H}$ NMR and MS (ES) 389 ( $\text{M} + \text{H}$ ) $^+$ .




**ER-807789**

[0272] To a suspension of **ER-807586** (5 mg, 0.0124 mmol, 1.0 eq.) in water (0.5 mL) was added  $\text{NH}_2\text{OMeHCl}$  (5.2 mg, 0.623 mmol, 50 eq.). The solid became soluble and saturated  $\text{NaHCO}_3$  (0.3 mL) was slowly added and the resulting mixture was stirred overnight. The reaction mixture was diluted with EtOAc and saturated  $\text{NaHCO}_3$ , and extracted with 4xEtOAc. The organic layers were combined, dried over  $\text{MgSO}_4$ , filtered and concentrated. The crude mixture was purified by silica gel chromatography (10% MeOH-EtOAc) to give **ER-807789** as a white solid (5.3 mg, 100%).  $^1\text{HNMR}$  and MS (ES) 432 ( $\text{M} + \text{H}$ ) $^+$ .




**ER-807790**

[0273] To a solution of **ER-807586** (15 mg) in MeOH-THF (1:1, 1 mL) was added  $\text{NaBH}_4$  (20 mg) and the mixture was stirred for 30 min, diluted with saturated  $\text{NaHCO}_3$  and extracted with 4xEtOAc. The organic layers were combined, dried over  $\text{MgSO}_4$ , filtered and concentrated. The crude mixture was purified by reverse HPLC (MeOH- $\text{H}_2\text{O}$ ) to give **ER-807790**.  $^1\text{HNMR}$  and MS (ES) 405.5 ( $\text{M} + \text{H}$ ) $^+$ .




**ER-807835**

[0274] To a solution of n-BuLi (1.6 M in hexanes, 0.35 mL, 0.56 mmol, 31.3 eq.) in THF (2.0 mL) at 0 °C was added methyl triphenylphosphonium bromide (0.20 g, 0.56 mmol, 31 eq.). The reaction was warmed to room temperature and stirred for 40 minutes. A portion of the solution (0.6 mL) was transferred to another flask and **ER-807586** (7.2 mg, 0.0179 mmol, 1.0 eq.) was added. The resulting mixture was stirred at room temperature for 18 hours and water was added and the mixture was extracted with 3xEtOAc. The organic layers were combined, dried over MgSO<sub>4</sub>, filtered and concentrated. The crude mixture was purified by reverse HPLC (MeOH-H<sub>2</sub>O) to give **ER-807835** (0.8 mg, 12 %). <sup>1</sup>H NMR and MS (ES) 401.5 (M + <sup>1</sup>H).



**ER-807837**

[0275] To a solution of **ER-807586** (11.5 mg, 0.0286 mmol, 1.0 eq.) in THF (2.0 mL) at 0 °C was added MeMgCl (3.0 M in THF, 0.25 mL, 0.75 mmol, 26.3 eq.). The reaction was warmed and stirred at room temperature for 18 hours. The reaction was quenched with saturated NaHCO<sub>3</sub>, and then was extracted with 3xEtOAc. The organic layers were combined, dried over MgSO<sub>4</sub>, filtered and concentrated. The resulting mixture was purified by silica gel chromatography (100% EtOAc, then 10% to 30% MeOH-EtOAc) to give **ER-807837** (0.8 mg, 7%). <sup>1</sup>H NMR and MS (ES) 419.4 (M + <sup>1</sup>H).




**ER-808036**

[0276] 5-chloromethyl-indole-1-carboxylic acid *tert*-butyl ester was prepared from **8** following the procedure for the preparation of **9** but without the addition of morpholine.


[0277] A mixture of 5-chloromethyl-indole-1-carboxylic acid *tert*-butyl ester (0.82 g, 3.10 mmol, 1.0 eq.), cyclohexyl mercaptan (0.53 mL, 1.4 eq.) and K<sub>2</sub>CO<sub>3</sub> (0.90 g, 2.0 eq.) in

DMF (6 mL) was heated at 40 °C until reaction completed. The reaction mixture was cooled to room temperature, diluted with sat. NH<sub>4</sub>Cl and extracted with diethyl ether. The organic extracts were dried over MgSO<sub>4</sub>, filtered and concentrated. The resulting mixture was purified by chromatography (5% EtOAc/hexanes) to give 5-cyclohexylsulfanylmethyl-indole-1-carboxylic acid *tert*-butyl ester (0.79 g, 74%).

[0278] **ER-808036** was prepared from 5-cyclohexylsulfanylmethyl-indole-1-carboxylic acid *tert*-butyl ester following the procedures for the preparation of **16** from **14**.




**ER-808082**



**ER-808083**

[0279] To a solution of **ER-808036** (60 mg, 0.15 mmol, 1.0 eq.) in THF (2.5 mL) and MeOH (1.5 mL) at -78 °C was added a solution of mCPBA (60 mg, ~70%, 1.6 eq.) in THF. After stirring for 2 h, the reaction was quenched by addition of sat. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and sat NaHCO<sub>3</sub>. The separated aqueous layer was extracted with 5x EtOAc, and the combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude mixture was purified by chromatography (5% to 10% MeOH/EtOAc) to give semipure products (18 mg and 32 mg each). After further purification by reverse phase HPLC (MeOH-water), **ER-808082** (3.2 mg) and **ER-808083** (3.2 mg) were obtained. <sup>1</sup>NMR confirmed both of the products.




**ER-808103**

[0280] A mixture of 5-chloromethyl-indole-1-carboxylic acid *tert*-butyl ester (0.41 g, 1.55 mmol, 1.0 eq.), cyclohexanol (0.82 mL, 5.0 eq.) and Ag<sub>2</sub>O (1.80 g, 5.0 eq.) in diethyl ether (5 mL) was stirred at 35 °C over weekend. After cooling to room temperature, the reaction mixture was filtered through celite washing with ether. The filtrate was concentrated and the

residue was purified by chromatography (3% EtOAc/hexanes) to give N-Boc-5-cyclohexyloxymethylindole (160 mg, 28%) as colorless oil. <sup>1</sup>HNMR confirmed the compound.


[0281] **ER-808103** was prepared from 5-cyclohexyloxymethyl-indole-1-carboxylic acid *tert*-butyl ester following the procedures for the preparation of **16** from **14**. Both MS (ES) and <sup>1</sup>HNMR confirmed the compound.



**ER-808040**

[0282] To a suspension of compound **3** (R=Me, 300 mg, 1.03  $\mu$ mol, 1.0 eq.) in THF (5 mL) at room temperature was added dropwise LiAlH<sub>4</sub> (1.0 M in THF, 2.56 mL, 2.5 eq.) and the resulting mixture was then heated at 65 °C for 30 min. After cooling to 0 °C, the reaction was quenched by addition of MeOH (1.2 mL, 30 eq.) and water (30 eq.), stirred and warmed to room temperature and filtered through celite washing with EtOAc. The filtrate was concentrated and the residue was purified by silica gel chromatography (EtOAc then 10% MeOH-EtOAc) to give 7-chloro-2-methyl-5-methylamino-3*H*-imidazo[4,5-*b*]pyridine as a white solid (190 mg, 94%).


[0283] **ER-808040** was prepared from 7-chloro-2-methyl-5-methylamino-3*H*-imidazo[4,5-*b*]pyridine and 5-[(cyclohexyl-methyl-amino)-methyl]-2-tributylstannanyl-indole-1-carboxylic acid *tert*-butyl ester (prepared from **8** and cyclohexyl-methyl-amine following the procedures for the preparation of **10**) following the procedure for the preparation of **13**. <sup>1</sup>HNMR confirmed the compound.



**ER-808128**


[0284] To a solution of **ER-807790** (17 mg, 0.042 mmol, 1.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) at 0 °C was added (MeOCH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NSF<sub>3</sub> (14  $\mu$ L, 1.8 eq.) and the resulting mixture was stirred for 1 h

at 0 °C and 1 h at room temperature. The reaction was quenched with sat. NaHCO<sub>3</sub> and the separated aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> followed by EtOAc-THF (1:1). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by reverse HPLC (MeOH-water) to give **ER-808128** (2 mg, 13%). <sup>1</sup>H NMR and MS confirmed the structure.



**5-formyl-indole-1-carboxylic acid *tert*-butyl ester or 6-formyl-indole-1-carboxylic acid *tert*-butyl ester**

[0285] To a solution of the **8** (8.0 g, 32.4 mmol, 1 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (24 mL) was added portionwise Dess-Martin reagent (17.9 g, 1.3 eq.) at 0 °C and the resulting mixture was warmed slowly to room temperature and stirred for 30 min. The reaction mixture was diluted with Et<sub>2</sub>O (100 mL), filtered through celite rinsing with Et<sub>2</sub>O (50 mL). The filtrate was washed with sat. NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude product was azeotroped with toluene to give 5-formyl-indole-1-carboxylic acid *tert*-butyl ester (7.3 g, 95%) or similarly 6-formyl-indole-1-carboxylic acid *tert*-butyl ester.




**ER-808281**

[0286] Mg (turnings) was activated by washing with 1N HCl and Et<sub>2</sub>O, and dried on high vacuum overnight. Bromomethylcyclohexane (0.8 mL, 1 eq.) in Et<sub>2</sub>O (4 mL) was added to the activated Mg (418 mg, 3 eq.) in Et<sub>2</sub>O (10 mL) slowly to keep the internal temperature at 30-33 °C. The resulting reaction mixture was heated at 34 °C for 1 h and cooled to 0 °C. A solution of 5-formyl-indole-1-carboxylic acid *tert*-butyl ester (900 mg) in Et<sub>2</sub>O (15 mL) was then introduced and the resulting mixture was warmed to room temperature, heated at 30-32 °C for 4 h, cooled to room temperature and then quenched with the addition of sat. NH<sub>4</sub>Cl. The separated aqueous phase was extracted with EtOAc, the combined organic layer was dried over MgSO<sub>4</sub>, filtered and

concentrated. The crude product was purified by chromatography (10% to 25% EtOAc/hexanes) to give the corresponding alcohol (949 mg, 85%).


[0287] To a mixture of the alcohol (513 mg, 1 eq.) and Et<sub>3</sub>N (625  $\mu$ L, 3 eq.) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) at 0 °C was added methanesulfonic anhydride (390 mg, 1.5 eq.). The cooling bath was removed and the resulting mixture was stirred for 2.5 h and diluted with sat. NaHCO<sub>3</sub>. The separated aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude product was purified by chromatography (hexanes to 10% EtOAc/hexanes) to give 5-(2-cyclohexyl-vinyl)-indole-1-carboxylic acid *tert*-butyl ester (380 mg, 78%).

[0288] **ER-808281** was prepared from 5-(2-cyclohexyl-vinyl)-indole-1-carboxylic acid *tert*-butyl ester following the procedures for the preparation of **16** from **14**. MS (ES) and <sup>1</sup>HNMR confirmed the compound.



**ER-808469**

[0289] A solution of **ER-808281** (~10 mg, 1 eq.) in MeOH (5 mL) with 10% Pd/C (catalytic) was kept under positive H<sub>2</sub> atmosphere overnight at room temperature. The mixture was then loaded onto silica gel eluting with EtOAc to 20% MeOH/EtOAc to give **ER-808469** (7.5 mg). MS (ES) and <sup>1</sup>HNMR confirmed the compound.




**5-vinyl-indole-1-carboxylic acid *tert*-butyl ester or 6-vinyl-indole-1-carboxylic acid *tert*-butyl ester**

[0290] To a suspension of methyltriphenylphosphonium bromide (8.1 g, 22.7 mmol) in THF (140 mL) at 0 °C was added nBuLi (1.6 M in hexanes, 14.2 mL, 22.7 mmol) dropwise over 10 min. After 20 min of stirring, a solution of the 5-formyl-indole-1-carboxylic acid *tert*-butyl ester (4.63 g, 14.8 mmol) in THF (20 mL) was introduced slowly over 20 min. The reaction was




warmed slowly to room temperature, stirred 30 min. The reaction mixture was poured into saturated ammonium chloride and the separated aqueous phase was extracted with ethylacetate (3x100 mL). The combined organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography (methylene chloride to 1% acetone-methylene chloride) to give 5-vinyl-indole-1-carboxylic acid *tert*-butyl ester (4.7 g, 100%) or similarly 6-vinyl-indole-1-carboxylic acid *tert*-butyl ester.



**5-(2-hydroxy-ethyl)-indole-1-carboxylic acid *tert*-butyl ester or 6-(2-hydroxy-ethyl)-indole-1-carboxylic acid *tert*-butyl ester**


[0291] To a solution of 5-vinyl-indole-1-carboxylic acid *tert*-butyl ester (4.5 g, 18.5 mmol, 1.0 eq.) in THF (46 mL) at 0 °C was added 9-BBN (0.5 M in THF, 87 mL, 2.4 eq.) over 10 min. The resulting reaction mixture was stirred for 2.5 h and diluted with THF (150 mL) and water (150 mL) while keeping the temperature at 0 °C. Then NaBO<sub>3</sub>·4H<sub>2</sub>O (44g) was introduced and resulting reaction mixture was stirred and warmed to room temperature and stirred. The reaction mixture was diluted with methylene chloride (100 mL) and the separated aqueous layer was extracted 3x100 mL methylene chloride. The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography (methylene chloride to 5% acetone/methylene chloride) to give 5-(2-hydroxy-ethyl)-indole-1-carboxylic acid *tert*-butyl ester (3.82 g, 76%) or similarly 6-(2-hydroxy-ethyl)-indole-1-carboxylic acid *tert*-butyl ester.



**5-(2-morpholin-4-yl-ethyl)-indole-1-carboxylic acid *tert*-butyl ester or 5-[2-(cyclohexyl-methyl-amino)-ethyl]-indole-1-carboxylic acid *tert*-butyl ester or 6-(2-morpholin-4-yl-ethyl)-indole-1-carboxylic acid *tert*-butyl ester or 6-[2-(cyclohexyl-methyl-amino)-ethyl]-indole-1-carboxylic acid *tert*-butyl ester**


[0292] To a solution of 5-(2-hydroxy-ethyl)-indole-1-carboxylic acid *tert*-butyl ester (260 mg, 1mmol, 1.0 eq.), triphenyl phosphine (391 mg, 1.5 eq.) and Imidazole (136 mg, 2 eq.) in

methylene chloride (5 mL) was added iodine (328 mg, 1.3eq.) in small portions over 20 min at room temperature. The reaction mixture was poured into water and extracted with 4x100 mL of methylene chloride. The combined organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (20% EtOAc/hexanes) to give a semipure iodide (600 mg). This iodide was then dissolved in MeOH (10 mL) and treated with morpholine (1.73 mL, 20 eq.) at 60 °C for overnight. The reaction mixture was cooled to room temperature, poured into water and extracted with methylene chloride. The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (methylene chloride to 15% acetone/methylene chloride) to give 5-(2-morpholin-4-yl-ethyl)-indole-1-carboxylic acid *tert*-butyl ester (290 mg, 88%) or similarly or 5-[2-(cyclohexyl-methyl-amino)-ethyl]-indole-1-carboxylic acid *tert*-butyl ester or 6-(2-morpholin-4-yl-ethyl)-indole-1-carboxylic acid *tert*-butyl ester or 6-[2-(cyclohexyl-methyl-amino)-ethyl]-indole-1-carboxylic acid *tert*-butyl ester.




**5-(2-methoxycarbonyl-vinyl)-indole-1-carboxylic acid *tert*-butyl ester or 6-(2-methoxycarbonyl-vinyl)-indole-1-carboxylic acid *tert*-butyl ester**

[0293] To a solution of the 5-formyl-indole-1-carboxylic acid *tert*-butyl ester (3.4 g, 13.8 mmol, 1.0 eq.) in toluene (35 mL) was added  $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Me}$  (5.5 g, 1.2 eq.) at room temperature and the resulting mixture was stirred overnight. After concentration, the crude product purified by silica gel column chromatography (methylene chloride to 1% acetone-methylene chloride) to give 5-(2-methoxycarbonyl-vinyl)-indole-1-carboxylic acid *tert*-butyl ester (5.03 g, 90%) or similarly 6-(2-methoxycarbonyl-vinyl)-indole-1-carboxylic acid *tert*-butyl ester.




**5-(3-hydroxy-propenyl)-indole-1-carboxylic acid *tert*-butyl ester or 6-(3-hydroxy-propenyl)-indole-1-carboxylic acid *tert*-butyl ester**

[0294] To a solution of methyl 5-(2-methoxycarbonyl-vinyl)-indole-1-carboxylic acid *tert*-butyl ester (4.64g, 15.3 mmol, 1.0 eq.) in THF (87 mL) at  $-30^{\circ}\text{C}$  was added  $\text{LiAlH}_4$  (1 N in THF, 18.6 mL, 1.2 eq.) by syringe pump over 20 min and the resulting mixture was stirred and warmed to  $-5^{\circ}\text{C}$ . After cooling back to  $-30^{\circ}\text{C}$ , the reaction was then quenched by slow addition of acetone (10 mL) keeping temperature below  $-15^{\circ}\text{C}$ , poured into Rochelle salt at  $0^{\circ}\text{C}$ , stirred for 1 h and the separated aqueous layer was extracted with EtOAc. The combined organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (methylene chloride to 2% acetone/methylene chloride) to give 5-(3-hydroxy-propenyl)-indole-1-carboxylic acid *tert*-butyl ester (2.89 g, 70%) or similarly 6-(3-hydroxy-propenyl)-indole-1-carboxylic acid *tert*-butyl ester.




**5-(3-morpholin-4-yl-propenyl)-indole-1-carboxylic acid *tert*-butyl ester or  
6-(3-morpholin-4-yl-propenyl)-indole-1-carboxylic acid *tert*-butyl ester**


[0295] To a solution 5-(3-hydroxy-propenyl)-indole-1-carboxylic acid *tert*-butyl ester (0.95 mg, 3.48 mmol, 1.0 eq.) and  $\text{Et}_3\text{N}$  (1.8 mL, 3.0 eq.) in methylene chloride (10 mL) at  $0^{\circ}\text{C}$  was added  $\text{MsCl}$  (0.40 mL, 1.5 eq.). The resulting mixture was stirred for 30 min and warmed to room temperature and stirred for additional 1 h. Then cyclohexyl-methyl-amine (8.3 mL, 18 eq.) was introduced and the resulting mixture was stirred over weekend, diluted with sat.  $\text{NaHCO}_3$  and the separated aqueous phase was extracted with 3x EtOAc. The combined organic phase was dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The residue was purified by silica gel chromatography (50% EtOAc/hexanes) to give **5-(3-morpholin-4-yl-propenyl)-indole-1-carboxylic acid *tert*-butyl ester** or similarly **6-(3-morpholin-4-yl-propenyl)-indole-1-carboxylic acid *tert*-butyl ester**.




**ER-808501**



**ER-808514**




**ER-8085042**




**ER-808544**

[0296] Analogs **ER-808501**, **ER-808514**, **ER-8085042** and **ER-808544** are prepared from 5-(2-morpholin-4-yl-ethyl)-indole-1-carboxylic acid *tert*-butyl ester, 5-(3-morpholin-4-yl-propenyl)-indole-1-carboxylic acid *tert*-butyl ester, 6-(3-morpholin-4-yl-propenyl)-indole-1-carboxylic acid *tert*-butyl ester and 6-(2-morpholin-4-yl-ethyl)-indole-1-carboxylic acid *tert*-butyl ester following the same procedures for the preparation of **16** from **14**.




**ER-809047**

[0297] A solution of **20** (51 mg) in methylene chloride (1 mL) was treated at room temperature with trifluoroacetic acid (1 mL) for 3 h and concentrated. The solid residue was washed with Et<sub>2</sub>O and MeOH to give crude product (18.2 mg). The crude product was then purified by reverse phase HPLC (MeOH-water) to give **ER-809047** (9.6 mg, 44%). MS (ES), <sup>19</sup>F and <sup>1</sup>HNMR confirmed the structure.




**IC-261**

[0298] A mixture of 7-chloro-3*H*-imidazo[4,5-*b*]pyridine (*J. Heterocyclic. Chem.* 1982, 19, 513) (250 mg, contain 25% of 5-chloro-3*H*-imidazo[4,5-*b*]pyridine), 2-tributylstannanyl-indole-1-carboxylic acid *tert*-butyl ester (**11**, 822 mg) and tetrakis(triphenylphosphine) palladium(0) (188 mg) in DMF (10 mL) was heated at 120°C for 6 h. The reaction mixture was extracted with AcOEt, and washed with water and brine. Organic layer was dried over MgSO<sub>4</sub> and evaporated. The residue was purified by chromatography (AcOEt/hexane) to give 7-(1*H*-indol-2-yl)-3*H*-imidazo[4,5-*b*]pyridine **IC-261** (28 mg) as a pale brown solid. <sup>1</sup>H NMR confirmed the structure.



**IC-395**


[0299] A mixture of **2** (1.66 g, 6 mmol), 2-tributylstannanyl-indole-1-carboxylic acid *tert*-butyl ester (**11**, 3.6 g, 7 mmol), triethylamine (0.83 ml, 6 mmol), and tetrakis(triphenylphosphine)palladium(0) (600 mg, 10 mol%) in DMF (10 mL) was heated at 130° C for 6 h. During the reaction, **11** was added in two portions (1.01g X 2). The reaction mixture was extracted with ethyl acetate and washed with water, and dried over anhydrous magnesium sulfate. After filtration, silica gel (400 mesh) was added to the residue and concentrated. The residue was purified by chromatography (AcOEt/MeOH) to give **IC-395** (240 mg) and **IC-375** (80 mg). <sup>1</sup>H NMR confirmed the structure.



**(7-chloro-2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-5-yl)-carbamic acid ethyl ester**


[0300] To a solution of diethyl 4-chloro-5-nitro-2,6-pyridinedicarbamate (intermediate for the preparation of **1**) (500 mg) in EtOH (50 mL) was added Raney Ni (1 g) and stirred for 12 h under hydrogen atmosphere at room temperature. Reaction mixture was filtered on celite and filtrate was concentrated under reduced pressure. Residue was dissolved in 2-propanol (10 mL)

and stirred for 60 h under reflux. The reaction mixture was cooled to room temperature and precipitate was filtered. The filtrate was concentrated to give 250 mg of (7-chloro-2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-5-yl)-carbamic acid ethyl ester as a gray solid. <sup>1</sup>H NMR confirmed the structure.




**IC-380**

[0301] A mixture of (7-chloro-2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-5-yl)-carbamic acid ethyl ester (240 mg), 2-tributylstannanyl-indole-1-carboxylic acid *tert*-butyl ester (**11**, 472 mg) and tetrakis(triphenylphosphine)palladium(0) (54 mg) in DMF (10 mL) was heated at 120 °C for 4 h. Additional 2-tributylstannanyl-indole-1-carboxylic acid *tert*-butyl ester (**11**, 472 mg) and tetrakis(triphenylphosphine) palladium(0) (54 mg) was introduced and the resulting mixture was heated at 120 °C for an additional 12 h. The reaction mixture was concentrated under reduced pressure and purified by chromatography (AcOEt/MeOH) to give **IC-380** (20 mg) as a pale gray solid. <sup>1</sup>H NMR confirmed the structure.




**(2-amino-7-chloro-3*H*-imidazo[4,5-*b*]pyridin-5-yl)-carbamic acid ethyl ester**

[0302] Cyanogen bromide (0.55 g, 5.2 mmol) was added to a stirred solution of ethyl 5,6-diamino-4-chloro-2-pyridinecarbamate (intermediate for the preparation of **1**, 1.00 g, 4.3 mmol) in 20 mL of ethanol at room temperature. The solution was stirred for 3 h and then at 60 °C for 3 h. The precipitate was filtered and washed with diethyl ether to give (2-amino-7-chloro-3*H*-imidazo[4,5-*b*]pyridin-5-yl)-carbamic acid ethyl ester (0.55 g, 38 %) as a yellow powder. <sup>1</sup>H NMR confirmed the structure.




**IC-416**

[0303] **IC-416** was obtained from (2-amino-7-chloro-3*H*-imidazo[4,5-*b*]pyridin-5-yl)-carbamic acid ethyl ester and **11** by using the typical procedure described for **IC-380**. <sup>1</sup>H NMR confirmed the structure.




**7-iodo-2-alkyl-3*H*-imidazo[4,5-*b*]pyridine**

[0304] Compound 7-iodo-2-alkyl-3*H*-imidazo[4,5-*b*]pyridine (7-iodo-3*H*-imidazo[4,5-*b*]pyridine, 7-iodo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine, 7-iodo-2-ethyl-3*H*-imidazo[4,5-*b*]pyridine) and /or its HI salt was prepared from 4-chloro-pyridine-2,3-diamine (Recueil, **1969**, 88, 1263-1274) following the same procedure for the preparation of **2** and **4** from **1**.




**5-fluoro-7-iodo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine**

[0305] To a solution of **4** ( $R_2$ =Me, HI mono-salt, 300 mg, 0.75 mmol, 1.0 eq.) in HBF<sub>4</sub> (48-51% in water, 3 mL) at 0 °C was added NaNO<sub>2</sub> (1.0 g, 19 eq.) portionwise over 1 h period keeping the reaction temperature under 4 °C. The resulting mixture was stirred at 0 °C for 40 min and at room temperature for 30 min. The reaction was then quenched with sat. NaHCO<sub>3</sub> and the resulting mixture was extracted with 5xEt<sub>2</sub>O. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give 5-fluoro-7-iodo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine as a light brown solid (170 mg, 86%). <sup>19</sup>FNMR, <sup>1</sup>HNMR and MS confirmed the structure.











[0306] Compound **66** was prepared from 7-iodo-2-alkyl-3*H*-imidazo[4,5-*b*]pyridine (or its HI mono-salt) or 5-fluoro-7-iodo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine and **15** following the same procedure for the preparation of **13** or **64**.





















[0307] Compound **67** was prepared from 7-iodo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine and **15** following the same procedure for the preparation of **65**.









ER-#	1. Structure of 66 or 67	<sup>1</sup> H NMR and/or MS
807496		<sup>1</sup> H NMR
807584		<sup>1</sup> H NMR
807585		<sup>1</sup> H NMR





















807587		<sup>1</sup> H NMR
807750		<sup>1</sup> H NMR
807787		<sup>1</sup> H NMR
807788		<sup>1</sup> H NMR
807865		<sup>1</sup> H NMR
808009		<sup>1</sup> H NMR
808081		<sup>1</sup> H NMR
808085		<sup>1</sup> H NMR










808160		<sup>1</sup> H NMR
808256		<sup>1</sup> H NMR
808257		<sup>1</sup> H NMR
808259		<sup>1</sup> H NMR
808260		<sup>1</sup> H NMR
808261		<sup>1</sup> H NMR
808262		<sup>1</sup> H NMR
808266		<sup>1</sup> H NMR
808268		<sup>1</sup> H NMR









808269		<sup>1</sup> H NMR
808284		<sup>1</sup> H NMR
808285		<sup>1</sup> H NMR
808286		<sup>1</sup> H NMR
808287		<sup>1</sup> H NMR
808288		<sup>1</sup> H NMR
808289		<sup>1</sup> H NMR
808291		<sup>1</sup> H NMR
808310		<sup>1</sup> H NMR

808311		$^1\text{H}$ NMR
808319		$^1\text{H}$ NMR
808322		$^1\text{H}$ NMR
808361		$^1\text{H}$ NMR
808362		$^1\text{H}$ NMR
808363		$^1\text{H}$ NMR
808370		$^1\text{H}$ NMR
808372		$^1\text{H}$ NMR











808385		<sup>1</sup> H NMR
808386		<sup>1</sup> H NMR
808388		<sup>1</sup> H NMR
808469		<sup>1</sup> H NMR
808470		<sup>1</sup> H NMR
808473		<sup>1</sup> H NMR
808496		<sup>1</sup> H NMR
808497		<sup>1</sup> H NMR
808498		<sup>1</sup> H NMR









808499		<sup>1</sup> H NMR
808500		<sup>1</sup> H NMR
808513		<sup>1</sup> H NMR
808541		<sup>1</sup> H NMR
808543		<sup>1</sup> H NMR
808571		<sup>1</sup> H NMR
808600		<sup>1</sup> H NMR
808617		<sup>1</sup> H NMR
808620		<sup>1</sup> H NMR









808622		<sup>1</sup> H NMR
808623		<sup>1</sup> H NMR
808624		<sup>1</sup> H NMR
808628		<sup>1</sup> H NMR
808629		<sup>1</sup> H NMR
808631		<sup>1</sup> H NMR
808635		<sup>1</sup> H NMR
808636		<sup>1</sup> H NMR
808637		<sup>1</sup> H NMR










808660		$^1\text{H}$ NMR
808672		$^1\text{H}$ NMR
808673		$^1\text{H}$ NMR
808691		$^1\text{H}$ NMR
808692		$^1\text{H}$ NMR
808703	 CF <sub>3</sub> CO <sub>2</sub> H	$^1\text{H}$ NMR
808704	 CF <sub>3</sub> CO <sub>2</sub> H	$^1\text{H}$ NMR
808705	 CF <sub>3</sub> CO <sub>2</sub> H	$^1\text{H}$ NMR




















808711		$^1\text{H}$ NMR
808712		$^1\text{H}$ NMR
808713		$^1\text{H}$ NMR
808714		$^1\text{H}$ NMR
808717		$^1\text{H}$ NMR
808719	 chiral	$^1\text{H}$ NMR
808720		$^1\text{H}$ NMR
808834		$^1\text{H}$ NMR
808835		$^1\text{H}$ NMR
808849		$^1\text{H}$ NMR



809187	 <chem>CN(C)Cc1ccc2c(c1)c[nH]2-c3cc4c(c[nH]3)c(F)nc4</chem> $\cdot \text{HI}$	$^1\text{H}$ NMR
809196	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809197	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809198	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809199	 $3 \text{ CF}_3\text{CO}_2\text{H}$	MS
809200	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809201	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809202	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS


809203	 <p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809204	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809205	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809206	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809207	 <p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809208	 <p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809209	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809210	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS

809211	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS
809212	 3 CF <sub>3</sub> CO <sub>2</sub> H	MS
809213	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS
809214	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS
809215	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS
809216	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS
809217	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS
809218	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS
809219	 2 CF <sub>3</sub> CO <sub>2</sub> H	MS

809220	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809221	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809222	 <p>3 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809223	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809224	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809225	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809226	 <p>2 CF<sub>3</sub>CO<sub>2</sub>H</p>	MS
809227	 <p>CF<sub>3</sub>CO<sub>2</sub>H</p>	MS


809228	 <chem>CC1=CN=C2C(=N1)C=CC=C2c3c[nH]c4ccc(cc34)C(=O)N(C)CC=C</chem> $\text{CF}_3\text{CO}_2\text{H}$	MS
809229	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809230	 $\text{CF}_3\text{CO}_2\text{H}$	MS
809231	 $\text{CF}_3\text{CO}_2\text{H}$	MS
809232	 $\text{CF}_3\text{CO}_2\text{H}$	MS
809233	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809234	 $2 \text{ CF}_3\text{CO}_2\text{H}$	MS
809235	 $\text{CF}_3\text{CO}_2\text{H}$	MS
809236	 $\text{CF}_3\text{CO}_2\text{H}$	MS

809237		MS
809238		MS




**7-iodo-2-methyl-1,4-dihydro-imidazo[4,5-b]pyridin-5-one**

[0308] To a solution of compound 4 (R=Me, 160 mg, 0.59 mmol) in 10 mL of 20% aqueous H<sub>2</sub>SO<sub>4</sub> at 0 °C was added sodium nitrite (1.54 mmol) in small portions and the resulting mixture was stirred at room temperature overnight. The reaction mixture was neutralized with sat. aqueous NH<sub>3</sub> to pH 7-8, and the resulting precipitate was collected to give a yellow solid. This solid was then crystallized in water to give 140 mg of product 7-iodo-2-methyl-1,4-dihydro-imidazo[4,5-b]pyridin-5-one (87%) with satisfactory MS and <sup>1</sup>H NMR.




**ER-807546**

[0309] **ER-807546** was prepared from 7-iodo-2-methyl-1,4-dihydro-imidazo[4,5-b]pyridin-5-one and 10 (R'=PhCH<sub>2</sub>, R''=Me) following the same procedure for the preparation of 13. Satisfactory MS and <sup>1</sup>H NMR were obtained for **ER-807546**.



**ER-809251**



**ER-809252**

[0310]        Analogs **ER-809251** and **ER-809252** are prepared from 7-iodo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine and 6-[2-(cyclohexyl-methyl-amino)-ethyl]-indole-1-carboxylic acid *tert*-butyl ester and 5-[2-(cyclohexyl-methyl-amino)-ethyl]-indole-1-carboxylic acid *tert*-butyl ester respectively following the same procedures for the preparation of **16** from **14**.

[0311]        3)        ***Biological Assays***

[0312]        ***HUVEC Assay Protocol:***

[0313]        Pooled human umbilical vein endothelial cells (HUVEC, Clonetics, Inc) were seeded in 96 well plates at  $5 \times 10^4$  cell/ml and incubated at 37°C. The following day, 20 µl of the each compound dilution was added to the cells and incubated for 30 minutes followed by stimulation with TNFα (1 ng/ml) for four hours at 37°C. After TNF stimulation, the plates were washed with PBS containing 0.5% BSA, fixed with 0.025% glutaraldehyde, and stained with primary and secondary antibodies for detection of E-selectin and ICAM expression. The plates were incubated with 100 µl of the primary murine anti-human E-selectin and anti-human ICAM antibody (R&D Systems, Minneapolis, MN) diluted 1:500 in PBS containing 0.5% BSA and 5% FBS for one hour after which the plates were washed and incubated with 100 µl of a secondary peroxidase conjugated goat anti-mouse IgG antibody (Pierce, Rockford, IL) diluted 1:10,000 in PBS/0.5%BSA/5%FBS for 30 minutes. The plates were then washed and 100 µl of TMB substrate was added and the color reaction was allowed to develop for 15-20 minutes. The reaction was stopped by the addition of 50 µl of 1 N H<sub>2</sub>SO<sub>4</sub> and the optical density (OD) was read on microplate spectrophotometer at 450 nm. IC<sub>50</sub> values were determined based on percent inhibition as calculated by the following formula:

$$\% \text{ Inhibition} = \left[ 1 - \left( \frac{(\text{avg. compound OD} - \text{avg. blank OD})}{(\text{avg. TNF OD} - \text{avg. blank OD})} \right) \right] * 100$$